Milk-Derived Microvesicle Compositions and Related Methods

ABSTRACT

A composition is provided that comprises a therapeutic agent encapsulated by a milk-derived microvesicle. The compositions can include therapeutic agents such as phytochemical agents or chemotherapeutic agents, while the milk-derived microvesicle can be derived from raw milk or colostrum. Further provided are methods for isolating a microvesicle that includes the steps of obtaining an amount of milk, and subjecting the milk to a series of sequential centrifugations configured to yield greater than about 300 mg of microvesicle protein per 100 ml of milk. Methods of modifying an immune response and treating a cancer in which a milk-derived microvesicle composition is administered are also provided.

RELATED APPLICATIONS

This application claims priority from U.S. Non-Provisional applicationSer. No. 15/910,322, filed Mar. 2, 2018, and from U.S. Non-Provisionalapplication Ser. No. 14/770,634, filed Aug. 26, 2015, and U.S.Provisional Application Ser. No. 61/769,551, filed Feb. 26, 2013, theentire disclosures of which are incorporated herein by this reference.

GOVERNMENT INTEREST

This invention was made with government support under grant numbersCA-118114 and CA-125152 awarded by the National Institutes of Health.The government has certain rights in the invention.

TECHNICAL FIELD

The presently-disclosed subject matter relates to milk-derivedmicrovesicle compositions and methods of isolating and using the samefor the treatment of disease. In particular, the presently-disclosedsubject matter relates to compositions that comprise therapeutic agentsencapsulated by milk-derived microvesicles and that are useful in thetreatment of disease.

BACKGROUND

Oral delivery of many compounds, natural or synthetic, generally resultsin limited bioavailability, and thus often requires large doses of thecompounds in order to achieve efficacy. Bolus doses of many suchcompounds though are not feasible in humans due to toxicity concerns ordue to the unavailability of compounds. Furthermore, some naturalcompounds, despite being administered in large doses (e.g., curcumin),have still resulted in limited bioavailability in pre-clinical andclinical studies due to poor absorption and rapid hepatic metabolism. Onthe other hand, chemotherapeutic agents often elicit dose spikes and arehighly toxic with severe short-term and long-term side effects. As such,compositions and methods that decrease dose-related toxicities whilemaintaining drug efficacy are considered to be of great importance.

In this regard, numerous laboratories have attempted to embed or attachcertain agents in liposomes, polymer-based formulations, ornanoparticles to improve oral bioavailability. Nevertheless, while theseapproaches have resulted in some improvements in bioavailability, thecarriers themselves, particularly polymer-based nanoparticles, can havetoxicity if not cleared effectively. Scalable production ofpolymer-based and other nanoparticles also continues to be a limitation.Recently, natural nanoparticles, such as exosomes having a size in therange of 30 to 100 nm size, have shown the potential to circumventproblems associated with traditional nanoparticles. However, the abilityto effectively encapsulate a specific therapeutic agent or an effectiveamount of a therapeutic agent in natural nanoparticles, such as anexosomes, has proven difficult in many instances. Additionally, currentapproaches of isolating exosomes from various body fluids, includingmilk, are based on differential centrifugation, sucrose-densitygradient, Sephadex chromatography, polymer-based (e.g., ExoQuick), andmany others. To date though, there are no procedures to isolate naturalnanoparticles, such as exosomes or other microvesicles, rapidly and inthe bulk quantities required for treating a disease on a commerciallevel.

SUMMARY

The presently-disclosed subject matter meets some or all of theabove-identified needs, as will become evident to those of ordinaryskill in the art after a study of information provided in this document.

This Summary describes several embodiments of the presently-disclosedsubject matter, and in many cases lists variations and permutations ofthese embodiments. This Summary is merely exemplary of the numerous andvaried embodiments. Mention of one or more representative features of agiven embodiment is likewise exemplary. Such an embodiment can typicallyexist with or without the feature(s) mentioned; likewise, those featurescan be applied to other embodiments of the presently-disclosed subjectmatter, whether listed in this Summary or not. To avoid excessiverepetition, this Summary does not list or suggest all possiblecombinations of such features.

The presently-disclosed subject matter includes milk-derivedmicrovesicle compositions and methods of isolating and using the samefor the treatment of disease. In particular, the presently-disclosedsubject matter includes compositions that comprise therapeutic agents,including both hydrophilic and lipophilic therapeutic agents, that areencapsulated by milk-derived microvesicles and that are useful in thetreatment of disease.

In some embodiments of the presently-disclosed subject matter, acomposition is provided that comprises an effective amount of atherapeutic agent encapsulated by a milk-derived microvesicle. In someembodiments, the milk-derived microvesicle is a colostrum-derivedmicrovesicle. In some embodiments, the milk-derived microvesicles formpart of a pharmaceutical composition, where the milk-derivedmicrovesicles are combined with a pharmaceutically-acceptable vehicle,carrier, or excipient.

With regard to the therapeutic agents that are encapsulated within amilk-derived microvesicle of the presently-disclosed subject matter, insome embodiments, the therapeutic agent is selected from the groupconsisting of a phytochemical agent and a chemotherapeutic agent. Forexample, in some embodiments, the therapeutic agent is a phytochemicalagent, such as curcumin, demethoxycurcumin, delphinidin, cyanidin,withaferin A, tanshinone, bilberry anthocyanidins, or combinationsthereof. In some embodiments, the therapeutic agent is a bilberryanthocyanidin mixture, punicalagin, or tanshinone. As another example,in other embodiments, the therapeutic agent is a chemotherapeutic agent,such as doxorubicin, paclitaxel, docetaxel, or combinations thereof. Infurther embodiments, the milk-derived microvesicles comprising one ormore miRNA molecules, such as, in certain embodiments, miR-155 andmiR-223.

Further provided, in some embodiments of the presently-disclosed subjectmatter, are methods for isolating a microvesicle. In some embodiments, amethod for isolating a microvesicle is provided that comprises the stepsof: obtaining an amount of milk; and subjecting the milk to a series ofsequential centrifugations that are configured to yield greater thanabout 50 mg (e.g., greater than about 300 mg) of microvesicle proteinper 100 ml of milk. For instance, in some embodiments, the series ofsequential centrifugations comprises a first centrifugation at 20,000×gat 4° C. for 30 min, a second centrifugation at 100,000×g at 4° C. for60 min, and a third centrifugation at 120,000×g at 4° C. for 90 min. Insome embodiments, the milk is raw milk and, in some embodiments, themilk is colostrum. In some embodiments, upon isolation, the isolatedmilk-derived microvesicles can then be stored at a concentration ofabout 5 mg/ml to about 10 mg/ml.

Still further provided, in some embodiments of the presently-disclosedsubject matter, are therapeutic methods wherein the milk-derivedmicrovesicles described herein are administered orally, intravenously,intranasally, or intraperitoneally to treat a disease or disorder in asubject. As one example of a therapeutic method, in some embodiments, amethod of modifying an immune response is provided that comprisesadministering to a subject in need thereof an effective amount of acomposition that includes a therapeutic agent encapsulated by amilk-derived microvesicle. In some embodiments of such methods,administering the composition reduces an amount of an inflammatorycytokine in a subject including, in certain embodiments, a reduction inthe amount of tumor necrosis factor-α, interleukin-1β, interferon γ,and/or interleukin-6. In some embodiments, administering the compositionreduces an amount of NF-κB signaling in a subject.

In other embodiments of the therapeutic methods, a method of treating acancer in a subject is provided that comprises administering to asubject in need thereof an effective amount of a composition including atherapeutic agent encapsulated by a milk-derived microvesicle. In someembodiments, the cancer is selected from the group consisting of breastcancer, uterine cancer, lung cancer, prostate cancer, ovarian cancer,cervical cancer, and pancreatic cancer. In some embodiments, thetherapeutic agent is selected from the group consisting of aphytochemical agent and a chemotherapeutic agent.

Further features and advantages of the present invention will becomeevident to those of ordinary skill in the art after a study of thedescription, figures, and non-limiting examples in this document.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 includes a graph and an image showing the sizes of exosomesderived from bovine mature milk and colostrum as measured by a NanoSightNanoparticle Tracking Instrument (Malvern Instruments, Westborough,Mass.), where, for the analysis, stock exosome suspension (6 mg/mlprotein concentration) was diluted 20-50 fold in phosphate-bufferedsaline (PBS) and a total of 200 μl was analyzed;

FIG. 2 includes a graph showing the size of exosomes derived from bovinemature milk and colostrum as measured by Zetasizer (Malvern InstrumentsLtd., Worcestershire, UK), where exosomes were analyzed using 1 ml ofthe diluted suspension (1 mg/ml);

FIG. 3 includes images showing the size measurement of exosomes derivedfrom bovine mature milk as measured by atomic force microscopy (AFM),where a diluted exosomal suspension was loaded on cleaned silicon wafersand air-dried for 30 min, and where Asylum MF-3D (Asylum Research,Oxford Instruments) AFM in 3D and tapping mode were used, silicon probescoated with aluminum coating (Force Constant=40 Nm-1; ResonantFrequency=300 kHz, Budget Sensors.com) were used for imaging, and wheretopographic height, amplitude and phase images were capturedconcurrently with a fixed force (<1 nN) with a scanning rate of 1 Hz;

FIG. 4 includes an image showing the size measurement of exosomesderived from bovine mature milk measured by scanning electron microscopy(SEM), where a milk exosomal suspension was filtered through a 0.22 μmfilter and loaded over clean silicon wafers and air-dried for 30 min,where silicon wafers were grounded using copper adhesive tape forconductivity, and where exosomes were imaged in Zeiss Supra 35 SEM underbeam energies (5 kV) at 142,000× magnification;

FIG. 5 includes an image showing separation of vehicle- andphytochemical agent-loaded bovine milk exosomes by sucrose densitygradient, where the indicated agents were initially mixed with theexosomes in the presence of 10% ethanol, excess or unbound drug wasremoved by centrifugation at 10,000×g for 10 min, and the phytochemicalagent-loaded exosomes were separated by centrifugation at 150,000×g on asucrose gradient using a 41 Ti swing rotor;

FIG. 6 is another image showing the separation of vehicle- andtherapeutic agent-loaded bovine colostrum exosomes by sucrose densitygradient, where curcumin was mixed with colostrum-derived exosomes inthe presence of 10% ethanol, excess or unbound curcumin was removed bycentrifugation at 10,000×g for 10 min, and the curcumin-loaded exosomeswere separated by centrifugation at 150,000×g on a sucrose gradientusing a 41 Ti swing rotor;

FIG. 7 includes an image showing separation of vehicle- and doxorubicin(DOX)-loaded bovine milk exosomes by sucrose density gradient, where DOXwas mixed with the exosomes in the presence of 10% ethanol, excess orunbound DOX was removed by centrifugation at 10,000×g for 10 min, andthe DOX loaded exosomes were separated by centrifugation at 150,000×g ona sucrose gradient using 41 Ti swing rotor;

FIG. 8 includes another image showing the separation of phytochemicalagent-loaded bovine colostrum exosomes by sucrose density gradient;

FIG. 9 includes images showing a dried powder of bovine milk-derivedexosomes and curcumin-loaded bovine milk-derived exosomes, where theexosomes alone (5 mg/ml) and the curcumin-loaded exosomes (5 mg/mlprotein containing 12% curcumin) were suspended inphosphate-buffered-saline (PBS) and dried by a nanospray apparatus usinga 0.45 μM pore size nozzle;

FIG. 10 includes a graph showing the kinetics of therapeutic agentrelease in vitro from withaferin A (WFA) loaded milk-exosomes, where therelease study was done using dialysis tubes against buffer containingthe surfactant, Tween-80 (0.02%) at 37° C., and where WFA extracted fromthe residual material was found to be stable during the workup, based onhigh pressure liquid chromatography analysis;

FIGS. 11A-11B includes graphs showing the kinetics of therapeutic agentrelease in vitro from chemotherapeutic agent-loaded milk exosomes, wherethe release study was done using dialysis tubes against buffercontaining the surfactant, Tween-80 (0.02%) at 37° C., and where thechemotherapeutic agents, paclitaxel (FIG. 11A) and docetaxel (FIG. 11B),extracted from the residual material were found to be stable during theworkup, based on the UV spectral analysis;

FIG. 12 includes images showing the uptake of bovine mature milk- andcolostrum-derived exosomes by human lung cancer cells, where 500 μg ofthe PKH67-labeled bovine milk and colostrum exosomes, or exosome alonewere added per 40,000 H1299 cells and incubated at 37° C. for 4 h, wherethe uptake of the fluorescently-labeled exosomes were detected byconfocal microscopy, and where alexa flour-phalloidin 549 was used todetect actin filaments, DAPI was used for the nucleus of the H1299cells, and PKH67 was used to label the exosomes;

FIG. 13 includes images showing the effect of endocytosis inhibitors onthe uptake of milk-derived exosomes, where human lung cancer H1299 cellswere treated with the indicated endocytosis inhibitors for 2 hrs,followed by PKH-26 labeled exosomes (50 μg exo protein/ml) for 4 hrs,and where cells were imaged using an AMG EVOS fluorescent microscope at20× magnification, while the gray images indicate cells in the field andwere taken at bright field;

FIG. 14 includes images showing the effect of time on uptake of milkexosomes, where human lung cancer (H1299) cells were treated with PKH-26labeled exosomes (50 μg exo protein/ml) for the indicated time, andwhere cells were imaged using a AMG EVOS fluorescent microscope at 20×magnification, with the gray images were taken at bright field;

FIG. 15 includes images showing siRNA loading into milk-derivedexosomes, where siRNA (BLOCK-iT™ Alexa Fluor® Red Fluorescent Control,Invitrogen) was used to load into milk exosome electroporation buffer,where the siRNA and milk exosome mixture was electroporated at 400 mVwith the pulse time of 10-15 ms, and where the electroporated mixturewas applied onto H1299 lung cancer cells and transfection efficiencyvisualized after 24 h under AMG EVOS fluorescent microscope at 10×magnification (scale 200 μm), with the gray images being captured underbright field;

FIG. 16 includes graphs showing the antiproliferative activity ofcurcumin-loaded milk exosomes versus free curcumin in human lung cancerA549 (left graph) and H1299 (right graph) cells, where Exo-Cur1 exosomalprotein concentration (μg/ml) was changed in parallel with curcuminconcentration, and where Exo-Cur2, exosomal protein concentration weremaintained constant (100 μg/ml);

FIG. 17 includes graphs showing the antiproliferative activity ofbilberry anthocyanidins-loaded milk exosomes versus free anthocyanidinsin human lung cancer A549 and H1299 cells, where anthocyanidins-loadedmilk exosomes and exosomal protein concentration were maintainedconstant (100 μg/ml);.

FIG. 18 includes graphs showing the antiproliferative activity ofwithaferin A-loaded milk exosomes versus free withaferin A in human lungcancer A549 and H1299 cells, where withaferin A-loaded milk exosomes andexosomal protein concentration were maintained constant (50 μg/ml).

FIG. 19 includes graphs showing the antiproliferative activity ofcurcumin-loaded milk exosomes versus free curcumin in human breastcancer T47D (left graph) and MDA-MB-231 (right graph) cells, wherebreast cancer T47D and MDA-MB-231 cells were treated with either 12.5 μMcurcumin or 45 μg/ml milk exosomes or curcumin-loaded milk exosomes(12.5 μM curcumin at 45 μg/ml exosomal protein), and where percent cellsurvival was analyzed by MTT assay;

FIG. 20 includes graphs showing the antiproliferative activity ofwithaferin A-loaded milk exosomes versus free withaferin A (WFA) inhuman Breast cancer T47D (left graph) and MDA-MB-231 (right graph)cells, where breast cancer cells were treated with WFA (0.6 μM) or WFAloaded milk exosomes (0.6 μM at 45 μg/ml exosomal protein) for 72 hrs;

FIG. 21 includes a graph showing the antiproliferative activity ofcurcumin-loaded milk exosomes versus free curcumin in human uterinecervical cancer (HeLa) cells, where HeLa cells were treated with either12.5 μM curcumin or 45 μg/ml milk exosomes or curcumin-loaded milkexosomes (12.5 μM curcumin at 45 μg/ml exosomal protein), and wherepercent cell survival was analyzed by MTT assay.

FIG. 22 includes a graph showing the antiproliferative activity ofwithaferin A-loaded milk exosomes versus free withaferin A in humancisplatin-resistant ovarian cancer OVCA 432 cells, where the withaferinA-loaded milk exosomes and the exosomal protein concentration wasmaintained constant (50 μg/ml), and where the proliferation weremeasured by MTT assay;

FIG. 23 includes a graph showing the antiproliferative activity ofwithaferin A-loaded milk exosomes versus free withaferin A in prostatecancer (DU145R) cells that are highly resistant to paclitaxel, wherewithaferin A-loaded milk exosomes and exosomal protein concentrationwere maintained constant (50 μg/ml);

FIG. 24 includes graphs showing the antiproliferative activity ofbilberry anthocyanidins-loaded milk exosomes versus free anthocyanidinsagainst prostate DU145 (left graph) and PC3 (right graph) cancer cells,where the bilberry anthocyanidins-loaded milk exosomes and exosomalprotein concentration were maintained constant (50 μg/ml);

FIG. 25 includes graphs showing the antiproliferative activity ofbilberry anthocyanidins-loaded milk exosomes versus free anthocyanidinsagainst pancreatic MIA PaCa2 (left graph) and S2013 (right graph) cancercells, where the bilberry anthocyanidins-loaded milk exosomes andexosomal protein concentration were maintained constant (50 μg/ml);

FIG. 26 includes graphs showing the anti-proliferative activity ofexosomes per se derived from bovine mature milk in human lung, breast,and uterine cervical cancer cells, where the cancer cells (lung, breast,and cervix) were treated with 50 μg/ml exosomal protein for 72 hrs, andwhere the percent survival was analyzed by MTT assay;

FIG. 27 includes graphs showing the antiproliferative activity ofcurcumin-loaded colostrum-derived exosomes in human lung, breast, anduterine cervical cancer cells, where lung A549 and H1299 cancer cellswere treated with curcumin (1.56 μM) exosomal protein (1.56 μg/ml), orcurcumin-loaded milk exosomes (1.56 μM at 3.12 μg/ml exosomal protein)for 72 hrs, and where the cervical HeLa cancer cells and breastMDA-MB-231 cancer cells were treated with either 12.5 μM curcumin or 45μg/ml milk exosomes or curcumin-loaded bovine colostrum exosomes (12.5μM curcumin at 45 μg/ml exosomal protein);

FIG. 28 includes a graph showing the biodistribution of DiR-labeledexosomes administered by oral gavage in nude mice, where differentorgans collected at euthanasia after 4 days of treatment were imaged onPhoton Imager Optima (Biospace lab) and relative intensity was measured;

FIG. 29 includes a graphs showing the biodistribution of DiR-labeledexosomes administered intravenously in nude mice, where different organscollected at euthanasia after 4 days of treatment were imaged on PhotonImager Optima (Biospace lab) and relative intensity was measured;

FIG. 30 includes a graph showing the biodistribution of DiR-labeled milkexosomes administered via intranasal route in nude mice, where differentorgans collected at euthanasia after 4 days of treatment were imaged onPhoton Imager Optima (Biospace) and relative intensity was measured;

FIG. 31 includes a graph showing the biodistribution of DiR-labeledexosomes administered by intraperitoneal route in nude mice, wheredifferent organs collected at euthanasia after 4 days of treatment wereimaged on Photon Imager Optima (Biospace lab) and relative intensity wasmeasured;

FIG. 32 includes graphs showing tissue distribution of curcumin in ratstreated with exosomal curcumin or free curcumin, where curcumin levelswere assessed in liver, lung, and brain tissues of female Sprague Dawleyrats treated with either free curcumin (0.5 mg/rat/day) orexosomal-curcumin (0.25 and 0.5 mg/rat/day) by oral gavage for 14 days;

FIG. 33 includes an image showing inhibition of constitutive and TNF-αinduced activation of the inflammation marker NF-κB by free curcumin (25μM) and curcumin-loaded bovine colostrum exosomes (25 μM curcumin; 90μg/ml exo protein), where human lung A549 cancer cells were pre-treatedwith exosomes (Exo), curcumin (Cur) or curcumin-loaded exosomes(Exo-cur) for 6 hrs followed by treatment with or without tumor necrosisfactor-alpha (TNF-α) (10 ng/ml) to induce NF-κB activation, and whereNF-κB levels were determined by electrophoretic mobility shift assay(EMSA).

FIG. 34 includes images showing the inhibition of constitutive and TNF-αinduced activation of the inflammation marker NF-κB by free curcumin (25μM) and curcumin-loaded bovine colostrum exosomes (25 μM curcumin; 90μg/ml Exo protein), where human lung H1299 cancer cells were pre-treatedwith exosomes (Exo), curcumin (Cur) or curcumin-loaded exosomes(Exo-cur) for 6 hrs followed by treatment with or TNF-α (10 ng/ml) toinduce NF-κB activation, and where NF-κB levels were determined by EMSA;

FIG. 35 includes an image showing inhibition of activation of theinflammation marker NF-κB by free curcumin (25 μM) and curcumin-loadedbovine colostrum-derived exosomes (25 μM curcumin; 90 μg/ml Exoprotein), where human breast MDA-MB-231 cancer cells were pre-treatedwith exosomes (Exo), curcumin (Cur) or curcumin-loaded exosomes(Exo-cur) for 6 hrs followed by treatment with or without TNF-α (10ng/ml) to induce NF-κB activation, and where NF-κB levels weredetermined by EMSA;

FIG. 36 includes images showing the inhibition of the lipopolysaccharide(LPS)-induced activation of the inflammation marker NF-κB by freecurcumin (25 μM) and curcumin-loaded bovine colostrum exosomes (25 μMcurcumin; 90 μg/ml Exo protein), where human lung (A549 and H1299)cancer cells were pre-treated with exosomes (Exo), curcumin (Cur) orcurcumin-loaded exosomes (Exo-cur) for 6 hrs followed by treatment withLPS (1 μg/ml) to induce NF-κB activation, and where NF-κB levels weredetermined by EMSA;

FIG. 37 includes images showing milk-derived exosome surface markers,where milk-derived exosomes isolated by ultracentrifugation wereanalyzed for exosomal surface markers CD63 and CD81 by western blotanalysis;

FIG. 38 includes images showing exosome-related surface markers, wheremilk- and colostrum-derived exosomes were analyzed for exosomal surfacemarkers (transpanins) CD63 and CD81 by western blot analysis;

FIG. 39 includes a graphs showing exosome-related mRNA expression, wherebovine milk- and colostrum-derived exosomes were analyzed for 8exosome-related mRNAs by RT-PCR;

FIG. 40 includes a graph showing that milk- and colostrum-derivedexosomes carry immune related miRNAs, where bovine milk- andcolostrum-derived exosomes were analyzed for five immune-related miRNAsby RT-PCR;

FIG. 41 includes a graph showing the immune response in macrophagesafter 6 hrs of treatment with lipopolysaccharide (LPS) (100 ng/ml) ormilk-derived exosomes (Exo-25=25 μg and Exo-100=100 μg Exo protein/ml)in cell culture;

FIG. 42 includes images showing the anti-inflammatory activity of bovinemilk-derived exosomes per se, where the inhibition of the constitutiveand TNF-α (10 ng/ml)-induced NF-κB in human lung cancer H1299 (A) andA549 (B) cells by milk exosomes (100 μg/ml) was measured by EMSA;

FIG. 43 includes an image showing the anti-inflammatory activity ofbovine milk-derived exosomes per se in the lung tissue of Sprague Dawleyrats treated with lipopolysaccharide (LPS) as measured by EMSA, whereSprague Dawley rats were treated with LPS (10 mg/kg) and milk exosomes(5 mg Exo protein/rat), both intraperitoneally, alone or in combinationfor 6 hrs;

FIG. 44 is a graph showing the antitumor activity of withaferin A(WFA)-loaded milk-derived exosomes, where following inoculation withhuman lung cancer A549 cells (3×10⁶ cells), when tumor xenografts grewto over 60 mm³, animals were treated intraperitoneally three times aweek with WFA-loaded exosomes (4 mg/kg WFA and 1.3 mg Exo protein/mouse)while two other groups were treated intraperitoneally with exosomesalone (1.3 mg/mouse) or WFA (4 mg/kg); and

FIG. 45 is a graph showing the anti-tumor activity of milk-derivedexosomes loaded with bilberry anthocyanidins, where followinginoculation with human lung cancer A549 cells (3×10⁶ cells), when tumorxenografts grew to over 60 mm³, nude mice were treated intraperitoneallythree times a week with anthocyanidins-loaded exosomes (0.25 mganthocyanidins and 1.3 mg Exo protein per mouse) while two other groupswere treated intraperitoneally with exosomes alone (1.3 mg/mouse) oranthocyanidins (0.25 mg/mouse).

DESCRIPTION OF EXEMPLARY EMBODIMENTS

The details of one or more embodiments of the presently-disclosedsubject matter are set forth in this document. Modifications toembodiments described in this document, and other embodiments, will beevident to those of ordinary skill in the art after a study of theinformation provided in this document. The information provided in thisdocument, and particularly the specific details of the describedexemplary embodiments, is provided primarily for clearness ofunderstanding and no unnecessary limitations are to be understoodtherefrom. In case of conflict, the specification of this document,including definitions, will control.

In certain instances, microRNAs (miRNAs) disclosed herein are identifiedwith reference to names assigned by the miRBase Registry (available atwww.mirbase.org). The sequences and other information regarding theidentified miRNAs as set forth in the miRBase Registry are expresslyincorporated by reference as are equivalent and related miRNAs presentin the miRBase Registry or other public databases. Also expresslyincorporated herein by reference are all annotations present in themiRBase Registry associated with the miRNAs disclosed herein. Unlessotherwise indicated or apparent, the references to the Sanger miRBaseRegistry are references to the most recent version of the database as ofthe filing date of this Application (i.e., mirBase 20, released June2013).

While the terms used herein are believed to be well understood by one ofordinary skill in the art, definitions are set forth herein tofacilitate explanation of the presently-disclosed subject matter.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which the presently-disclosed subject matter belongs.Although any methods, devices, and materials similar or equivalent tothose described herein can be used in the practice or testing of thepresently-disclosed subject matter, representative methods, devices, andmaterials are now described.

Following long-standing patent law convention, the terms “a”, “an”, and“the” refer to “one or more” when used in this application, includingthe claims. Thus, for example, reference to “a cell” includes aplurality of such cells, and so forth.

Unless otherwise indicated, all numbers expressing quantities ofingredients, properties such as reaction conditions, and so forth usedin the specification and claims are to be understood as being modifiedin all instances by the term “about”. Accordingly, unless indicated tothe contrary, the numerical parameters set forth in this specificationand claims are approximations that can vary depending upon the desiredproperties sought to be obtained by the presently-disclosed subjectmatter.

As used herein, the term “about,” when referring to a value or to anamount of mass, weight, time, volume, concentration or percentage ismeant to encompass variations of in some embodiments ±20%, in someembodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, insome embodiments ±0.5%, and in some embodiments ±0.1% from the specifiedamount, as such variations are appropriate to perform the disclosedmethod.

As used herein, ranges can be expressed as from “about” one particularvalue, and/or to “about” another particular value. It is also understoodthat there are a number of values disclosed herein, and that each valueis also herein disclosed as “about” that particular value in addition tothe value itself. For example, if the value “10” is disclosed, then“about 10” is also disclosed. It is also understood that each unitbetween two particular units are also disclosed. For example, if 10 and15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

Microvesicles are naturally existing particles that are in the form ofsmall assemblies of lipid particles, are about 30 to 1000 nm in size,and are not only secreted by many types of in vitro cell cultures and invivo cells, but are commonly found in vivo in body fluids, such asblood, urine and malignant ascites. Indeed, microvesicles include, butare not limited to, particles such as exosomes, epididimosomes,argosomes, exosome-like vesicles, microparticles, promininosomes,prostasomes, dexosomes, texosomes, dex, tex, archeosomes, and oncosomes.

As noted above, microvesicles can be formed by a variety of processes,including the release of apoptotic bodies, the budding of microvesiclesdirectly from the cytoplasmic membrane of a cell, and exocytosis frommultivesicular bodies. For example, exosomes are commonly formed bytheir secretion from the endosomal membrane compartments of cells as aconsequence of the fusion of multivesicular bodies with the plasmamembrane. The multivesicular bodies (MVBs) are formed by inward buddingfrom the endosomal membrane and subsequent pinching off of smallvesicles into the luminal space. The internal vesicles present in theMVBs are then released into the extracellular fluid as so-calledexosomes.

As part of the formation and release of microvesicles, unwantedmolecules are eliminated from cells. However, cytosolic and plasmamembrane proteins are also incorporated during these processes into themicrovesicles, resulting in microvesicles having particle sizeproperties, lipid bilayer functional properties, and other uniquefunctional properties that allow the microvesicles to potentiallyfunction as effective nanoparticle carriers of therapeutic agents. Inthis regard, the term “microvesicle” is used interchangeably herein withthe terms “nanoparticle,” “liposome,” “exosome,” “exosome-likeparticle,” “nano-vector” and grammatical variations of each of theforegoing.

With further regard to the functional properties of microvesicles, ithas now been discovered that milk, including colostrum, is not only aviable source of large quantities of microvesicles, but thatmicrovesicles derived from milk can be used as an effective deliveryvehicle for a number of therapeutic agents and can be used in a mannerthat retains the biological activity, including the bioavailability, ofthe therapeutic agents.

The presently-disclosed subject matter thus includes milk-derivedmicrovesicle compositions that can be used to encapsulate a variety oftherapeutic agents and are useful in the treatment of various diseases,including cancers. In some embodiments of the presently-disclosedsubject matter, a microvesicle composition is provided that comprises aneffective amount of a therapeutic agent encapsulated by a milk-derivedmicrovesicle. In some embodiments, the therapeutic agent encapsulated bythe milk-derived microvesicle is selected from a phytochemical agent ora chemotherapeutic agent.

The term “milk” is used herein to describe the opaque liquid thatcontains proteins, fats, lactose, and various vitamins and minerals andthat is produced by the mammary glands of mature female mammalsincluding, but not limited to, after the mammals have given birth toprovide nourishment for their young. In this regard, in someembodiments, the term “milk” is further inclusive of colostrum, or theliquid that is secreted by the mammary glands of mammals at the time ofparturition and that is rich in antibodies and minerals. In someembodiments, the compositions of the presently-disclosed subject matterare comprised of colostrum-derived microvesicles.

The phrase “milk-derived” or “colostrum-derived,” when used in thecontext of a microvesicle derived from milk or colostrum, refers to amicrovesicle that, by the hand of man, exists apart from its nativeenvironment and is therefore not a product of nature. In this regard,the phrases “milk-derived” microvesicles or “colostrum-derived”microvesicles is used interchangeably herein with the phrases “milkmicrovesicles” or “colostrum microvesicles,” respectively to refer tomicrovesicles that have been isolated from milk or colostrum.Additionally, in some embodiments, the phrase “milk-derived” can be usedinterchangeably with the phrase “isolated from milk” to describe amicrovesicle of the presently-disclosed subject matter that is usefulfor encapsulating therapeutic agents.

In some embodiments, the isolation of microvesicles is achieved bycentrifuging raw (i.e., unpasteurized milk or colostrum) at high speedsto isolate the microvesicles. In one preferred embodiment, themicrovesicles of the presently-disclosed subject matter are isolated ina manner that allows for the isolation of clinical-grade microvesiclesin amounts greater than about 50 mg (e.g., greater than about 300 mg) ofmicrovesicle protein per 100 ml of milk. In this regard, in someembodiments, a method of isolating a microvesicles is further providedthat includes the steps of: obtaining an amount of milk (e.g., raw milkor colostrum); and subjecting the milk to a series of sequentialcentrifugations configured to yield greater than about 50 mg of exosomalprotein per 100 ml of milk. In some embodiments, the sequentialcentrifugations yield greater than 300 mg of exosomal protein per 100 mlof milk. In some embodiments, the series of sequential centrifugationscomprises a first centrifugation at 20,000×g at 4° C. for 30 min, asecond centrifugation at 100,000×g at 4° C. for 60 min, and a thirdcentrifugation at 120,000×g at 4° C. for 90 min. In some embodiments,the isolated microvesicles can then be stored at a concentration ofabout 5 mg/ml to about 10 mg/ml as such a concentration has been foundto prevent coagulation and allow the isolated microvesicles toeffectively be used for the encapsulation of one or more therapeuticagents. In some embodiments, the isolated microvesicles are passedthrough a 0.22 μm filter to remove any coagulated particles as well asmicroorganisms, such as bacteria.

The phrase “encapsulated by a microvesicle,” or grammatical variationsthereof is used herein to refer to microvesicles whose lipid bilayersurrounds a therapeutic agent. For example, a reference to “microvesiclecurcumin” refers to a microvesicle whose lipid bilayer encapsulates orsurrounds an effective amount of curcumin. In some embodiments, theencapsulation of various therapeutic agents within microvesicles can beachieved by mixing the one or more of the phytochemical agents orchemotherapeutic agents with isolated microvesicles in a suitablesolvent, such as ethanol. After a period of incubation sufficient toallow the therapeutic agent to become encapsulated during the incubationperiod, the microvesicle/therapeutic agent mixture is then subjected toa low-speed centrifugation (e.g., 10,000×g) to remove any unboundtherapeutic agent and one or more high-speed centrifugationcentrifugations to isolate the microvesicles encapsulating thetherapeutic agents.

As used herein, the term “therapeutic agent” is used to refer to anagent that is capable of “treating” a disease, as defined herein below.As noted above, in some embodiments, the therapeutic agent can comprisea phytochemical agent or a chemotherapeutic agent.

The term “phytochemical agent” refers to a non-nutritive plant-derivedcompound, or an analog thereof, that is capable of “treating” a disease,as defined herein below. Examples of phytochemical agents include, butare not limited to compounds such as monophenols; flavonoids, such asflavonols, flavanones, flavones, flavan-3-ols, anthocyanins,anthocyanidins, isoflavones, dihydroflavonols, chalcones, andcoumestans; phenolic acids; hydroxycinnamic acids; lignans; tyrosolesters; stillbenoids; hydrolysable tannins; carotenoids, such ascarotenes and xanthophylls; monoterpenes; saponins; lipids, such asphytosterols, tocopherols, and omega-3,6,9 fatty acids; diterpenes;triterpinoids; betalains, such as betacyanins and betaxanthins;dithiolthiones; thiosulphonates; indoles; and glucosinolates. As anotherexample of a phytochemical agent disclosed herein, the phytochemicalagent can be an analog of a plant-derived compound, such as oltipraz,which is an analog of 1,2-dithiol-3-thione, a compound that is found inmany cruciferous vegetables. Table 1 provides a list of specificphytochemical agents that are exemplary of the broader classes ofphytochemical agents described herein above.

In some embodiments, the phytochemical agent is selected from curcumin,demethoxycurcumin, delphinidin, cyanidin, withaferin A, tanshinone, amixture of anthocyanidins (e.g., bilberry anthocyanidins), orcombinations thereof. In some embodiments, the phytochemical agent is abilberry anthocyanidin mixture, punicalagin, tanshinone II, orcombinations thereof. In some embodiments, the phytochemical agent iscurcumin or Withaferin A. In some embodiments, the phytochemical agentis a bilberry anthocyanin mixture which includes, in certainembodiments, a mixture of five anthocyanidins isolated fromanthocyanin-enriched bilberry extract following acid hydrolysis andpurification by solid-phase or solvent-solvent extraction. In someembodiments, the mixture of five anthocyanidins is a mixture ofdelphinidin, cyanidin, malvidin, peonidin, and petunidin.

TABLE 1 List of Exemplary Phytochemical Agents. PHENOLIC COMPOUNDSTERPENES BETALAINS Monophenols Flavonoids (polyphenols) CarotenoidsBetalains Apiole Flavonols (tetraterpenoids) Betacyanins CarnosolQuercetin Carotenes Betanin Carvacrol Gingerol α-Carotene IsobetaninDillapiole Kaempferol β-Carotene Probetanin Rosemarinol Myricetinγ-Carotene Neobetanin Phenolic acids Rutin δ-Carotene BetaxanthinsEllagic acid Isorhamnetin Tocotrienols Indicaxanthin Gallic acidFlavanones Tocopherols Vulgaxanthin Salicylic acid Hesperidin LycopeneORGANOSULFIDES Tannic acid Naringenin Neurosporene DithiolthionesVanillin Silybin Phytofluene Sulphoraphane Capsaicin EriodictyolPhytoene Thiosulphonates Curcumin Flavones Xanthophylls Allyl methyltrisulfide Plumbagin Apigenin Canthaxanthin Dialyl sulfideHydroxycinnamic Tangeritin Cryptoxanthin INDOLES, acids LuteolinZeaxanthin GLUCOSINOLATES Caffeic acid Flavan-3-ols AstaxanthinIndole-3-carbinol Chlorogenic acid Catechins Lutein sulforaphoneCinnamic acid Gallocatechin Rubixanthin 3,3′-Diindolylmethane Ferulicacid Epicatechin Monoterpenes Sinigrin Coumarin EpigallocatechinLimonene Allicin Lignans Epigallocatechin gallate Perillyl alcoholAlliin (phytoestrogens) Epicatechin-gallate Saponins Allylisothiocyanate Silymarin Theaflavin Lipids Piperine MatairesinolTheaflavin-gallate Phytosterols SecoisolariciresinolTheaflavin-digallate Campesterol Pinoresinol Thearubigins β-SitosterolLariciresinol Anthocyanins γ-Sitosterol Tyrosol esters & AnthocyanidinsStigmasterol Tyrosol Pelargonidin Tocopherols Hydroxytyrosol Peonidinω-3,6,9 fatty acids Oleocanthal Cyanidin γ-linolenic acid OleuropeinDelphinidin Triterpenoid Stilbenoids Malvidin Withaferin A ResveratrolPetunidin Oleanolic acid Pterostilbene Isoflavones (phytoestrogens)Ursolic acid Piceatannol Daidzein Betulinic acid Hydrolyzable TanninsGenistein Moronic acid Punicalagins Equol Curcurbitacins GlyciteinLupeol Dihydroflavonols Chalcones Coumestans Coumestrol

As also noted herein above, in some embodiments of thepresently-disclosed subject matter, the therapeutic agent that isencapsulated within the exosome is a chemotherapeutic agent. Examples ofchemotherapeutic agents that can be used in accordance with thepresently-disclosed subject matter include, but are not limited to,platinum coordination compounds such as cisplatin, carboplatin oroxalyplatin; taxane compounds, such as paclitaxel or docetaxel;topoisomerase I inhibitors such as camptothecin compounds for exampleirinotecan or topotecan; topoisomerase II inhibitors such as anti-tumorpodophyllotoxin derivatives for example etoposide or teniposide;anti-tumor vinca alkaloids for example vinblastine, vincristine orvinorelbine; anti-tumor nucleoside derivatives for example5-fluorouracil, gemcitabine or capecitabine; alkylating agents, such asnitrogen mustard or nitrosourea for example cyclophosphamide,chlorambucil, carmustine or lomustine; anti-tumor anthracyclinederivatives for example daunorubicin, doxorubicin, idarubicin ormitoxantrone; HER2 antibodies for example trastuzumab; estrogen receptorantagonists or selective estrogen receptor modulators for exampletamoxifen, toremifene, droloxifene, faslodex or raloxifene; aromataseinhibitors, such as exemestane, anastrozole, letrazole and vorozole;differentiating agents such as retinoids, vitamin D and retinoic acidmetabolism blocking agents (RAMBA) for example accutane; DNA methyltransferase inhibitors for example azacytidine; kinase inhibitors forexample flavoperidol, imatinib mesylate or gefitinib;farnesyltransferase inhibitors; HDAC inhibitors; other inhibitors of theubiquitin-proteasome pathway for example VELCADE® (MillenniumPharmaceuticals, Cambridge, Mass.); or YONDELIS® (Johnson & Johnson, NewBrunswick, N.J.). In some embodiments, the chemotherapeutic agent thatis encapsulated by an exosome in accordance with the presently-disclosedsubject matter is selected from retinoic acid, 5-fluorouracil,vincristine, actinomycin D, adriamycin, cisplatin, docetaxel,doxorubicin, and taxol. In some embodiments, the chemotherapeutic agentis doxorubicin, docetaxel, paclitaxel, or a combination thereof.

In some embodiments, the microvesicle composition described hereinfurther includes one or more microRNAs (miRNAs), either by virtue ofbeing present in the microvesicles upon their isolation or by virtue ofartificially encapsulating one or more miRNAs into the microvesiclessubsequent to their initial isolation. As would be recognized by thoseskilled in the art, miRNAs are naturally occurring, small non-codingRNAs that are about 17 to about 25 nucleotide bases (nt) in length intheir biologically active form. miRNAs post-transcriptionally regulategene expression by repressing target mRNA translation. It is thoughtthat miRNAs function as negative regulators, i.e. greater amounts of aspecific miRNA will correlate with lower levels of target geneexpression. There are three forms of miRNAs existing in vivo, primarymiRNAs (pri-miRNAs), premature miRNAs (pre-miRNAs), and mature miRNAs.Primary miRNAs are expressed as stem-loop structured transcripts ofabout a few hundred bases to over 1 kb. The pri-miRNA transcripts arecleaved in the nucleus by an RNase II endonuclease called Drosha thatcleaves both strands of the stem near the base of the stem loop. Droshacleaves the RNA duplex with staggered cuts, leaving a 5′ phosphate and 2nt overhang at the 3′ end. The cleavage product, the premature miRNA(pre-miRNA) is about 60 to about 110 nt long with a hairpin structureformed in a fold-back manner. Pre-miRNA is transported from the nucleusto the cytoplasm by Ran-GTP and Exportin-5. Pre-miRNAs are processedfurther in the cytoplasm by another RNase II endonuclease called Dicer.Dicer recognizes the 5′ phosphate and 3′ overhang, and cleaves the loopoff at the stem-loop junction to form miRNA duplexes. The miRNA duplexbinds to the RNA-induced silencing complex (RISC), where the antisensestrand is preferentially degraded and the sense strand mature miRNAdirects RISC to its target site. It is the mature miRNA that is thebiologically active form of the miRNA and is about 17 to about 25 nt inlength. In some embodiments, the miRNAs encapsulated by themicrovesicles of the presently-disclosed subject matter are selectedfrom miR-155, which is known to act as regulator of T- and B-cellmaturation and the innate immune response, or miR-223, which is known asa regulator of neutrophil proliferation and activation.

In some embodiments of the presently-disclosed subject matter,pharmaceutical compositions included the milk-derived exosomes arefurther provided. In some embodiments, a pharmaceutical composition isprovided that comprises a milk-derived microvesicle compositiondisclosed herein and a pharmaceutical vehicle, carrier, or excipient. Insome embodiments, the pharmaceutical composition ispharmaceutically-acceptable in humans. Also, as described further below,in some embodiments, the pharmaceutical composition can be formulated asa therapeutic composition for delivery to a subject.

A pharmaceutical composition as described herein preferably comprises acomposition that includes pharmaceutical carrier such as aqueous andnon-aqueous sterile injection solutions that can contain antioxidants,buffers, bacteriostats, bactericidal antibiotics and solutes that renderthe formulation isotonic with the bodily fluids of the intendedrecipient; and aqueous and non-aqueous sterile suspensions, which caninclude suspending agents and thickening agents. The pharmaceuticalcompositions used can take such forms as suspensions, solutions oremulsions in oily or aqueous vehicles, and can contain formulatoryagents such as suspending, stabilizing and/or dispersing agents.Additionally, the formulations can be presented in unit-dose ormulti-dose containers, for example sealed ampoules and vials, and can bestored in a frozen or freeze-dried or room temperature (lyophilized)condition requiring only the addition of sterile liquid carrierimmediately prior to use.

In some embodiments, solid formulations of the compositions for oraladministration can contain suitable carriers or excipients, such as cornstarch, gelatin, lactose, acacia, sucrose, microcrystalline cellulose,kaolin, mannitol, dicalcium phosphate, calcium carbonate, sodiumchloride, or alginic acid. Disintegrators that can be used include, butare not limited to, microcrystalline cellulose, corn starch, sodiumstarch glycolate, and alginic acid. Tablet binders that can be usedinclude acacia, methylcellulose, sodium carboxymethylcellulose,polyvinylpyrrolidone, hydroxypropyl methylcellulose, sucrose, starch,and ethylcellulose. Lubricants that can be used include magnesiumstearates, stearic acid, silicone fluid, talc, waxes, oils, andcolloidal silica. Further, the solid formulations can be uncoated orthey can be coated by known techniques to delay disintegration andabsorption in the gastrointestinal tract and thereby provide asustained/extended action over a longer period of time. For example,glyceryl monostearate or glyceryl distearate can be employed to providea sustained-/extended-release formulation. Numerous techniques forformulating sustained release preparations are known to those ofordinary skill in the art and can be used in accordance with the presentinvention, including the techniques described in the followingreferences: U.S. Pat. Nos. 4,891,223; 6,004,582; 5,397,574; 5,419,917;5,458,005; 5,458,887; 5,458,888; 5,472,708; 6,106,862; 6,103,263;6,099,862; 6,099,859; 6,096,340; 6,077,541; 5,916,595; 5,837,379;5,834,023; 5,885,616; 5,456,921; 5,603,956; 5,512,297; 5,399,362;5,399,359; 5,399,358; 5,725,883; 5,773,025; 6,110,498; 5,952,004;5,912,013; 5,897,876; 5,824,638; 5,464,633; 5,422,123; and 4,839,177;and WO 98/47491, each of which is incorporated herein by this reference.

Liquid preparations for oral administration can take the form of, forexample, solutions, syrups or suspensions, or they can be presented as adry product for constitution with water or other suitable vehicle beforeuse. Such liquid preparations can be prepared by conventional techniqueswith pharmaceutically-acceptable additives such as suspending agents(e.g., sorbitol syrup, cellulose derivatives or hydrogenated ediblefats); emulsifying agents (e.g. lecithin or acacia); non-aqueousvehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionatedvegetable oils); and preservatives (e.g., methyl orpropyl-p-hydroxybenzoates or sorbic acid). The preparations can alsocontain buffer salts, flavoring, coloring and sweetening agents asappropriate. Preparations for oral administration can be suitablyformulated to give controlled release of the active compound. For buccaladministration, the compositions can take the form of capsules, tabletsor lozenges formulated in conventional manner.

Various liquid and powder formulations can also be prepared byconventional methods for inhalation into the lungs of the subject to betreated or for intranasal administration into the nose and sinuscavities of a subject to be treated. For example, the compositions canbe conveniently delivered in the form of an aerosol spray presentationfrom pressurized packs or a nebulizer, with the use of a suitablepropellant, e.g., dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.Capsules and cartridges of, for example, gelatin for use in an inhaleror insufflator may be formulated containing a powder mix of the desiredcompound and a suitable powder base such as lactose or starch.

The compositions can also be formulated as a preparation forimplantation or injection. Thus, for example, the compositions can beformulated with suitable polymeric or hydrophobic materials (e.g., as anemulsion in an acceptable oil) or ion exchange resins, or as sparinglysoluble derivatives (e.g., as a sparingly soluble salt).

The compositions can further be formulated as topical semi-sold ointmentor cream formulations can contain a concentration of thepresently-described microvesicle compositions in a carrier such as apharmaceutical cream base. Various formulations for topical use includedrops, tinctures, lotions, creams, solutions, and ointments containingthe active ingredient and various supports and vehicles. The optimalpercentage of the therapeutic agent in each pharmaceutical formulationvaries according to the formulation itself and the therapeutic effectdesired in the specific pathologies and correlated therapeutic. In someembodiments, such ointment or cream formulations can be used fortrans-dermal delivery of the pharmaceutical compositions describedherein or for delivery to organs such as vagina or cervix in women.

Injectable formulations of the compositions can contain various carrierssuch as vegetable oils, dimethylacetamide, dimethylformamide, ethyllactate, ethyl carbonate, isopropyl myristate, ethanol, polyols(glycerol, propylene glycol, liquid polyethylene glycol), and the like.For intravenous injections, water soluble versions of the compositionscan be administered by the drip method, whereby a formulation includinga pharmaceutical composition of the presently-disclosed subject matterand a physiologically-acceptable excipient is infused.Physiologically-acceptable excipients can include, for example, 5%dextrose, 0.9% saline, Ringer's solution or other suitable excipients.Intramuscular preparations, e.g., a sterile formulation of a suitablesoluble salt form of the compounds, can be dissolved and administered ina pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or5% glucose solution. A suitable insoluble form of the composition can beprepared and administered as a suspension in an aqueous base or apharmaceutically-acceptable oil base, such as an ester of a long chainfatty acid, (e.g., ethyl oleate).

In addition to the formulations described above, the microvesiclecompositions of the presently-disclosed subject matter can also beformulated as rectal compositions, such as suppositories or retentionenemas, e.g., containing conventional suppository bases such as cocoabutter or other glycerides. Further, the microvesicle compositions canalso be formulated as a depot preparation by combining the compositionswith suitable polymeric or hydrophobic materials (for example as anemulsion in an acceptable oil) or ion exchange resins, or as sparinglysoluble derivatives, for example, as a sparingly soluble salt.

Further provided, in some embodiments of the presently-disclosed subjectmatter, are methods for modifying an immune response in a subject. Asused herein, the term “immune response” includes responses which arecaused, at least in part, or mediated, by the immune system of anindividual. In some embodiments, a method for modifying an immuneresponse is provided that comprises administering to a subject in needthereof an effective amount of a microvesicle composition of thepresently-disclosed subject matter, wherein the microvesicle included inthe composition is derived from milk. In some embodiments of the methodsfor modifying an immune response, the therapeutic agent is selected froma phytochemical agent or an miRNA. For example, in some embodiments, thetherapeutic agent is a phytochemical agent and an effective amount ofcurcumin, demethoxycurcumin, delphinidin, cyanidin, withaferin A,tanshinone, bilberry anthocyanidins, or combinations thereof areadministered to a subject to thereby modify and immune response. Asanother example, in some embodiments, the therapeutic agent is an miRNAand an effective amount of miR-155, miR-223, or a combination thereof isadministered to a subject to thereby modify an immune response.

For administration of a therapeutic composition as disclosed herein(e.g., a milk-derived microvesicle encapsulating a therapeutic agent),conventional methods of extrapolating human dosage based on dosesadministered to a murine animal model can be carried out using theconversion factor for converting the mouse dosage to human dosage: DoseHuman per kg=Dose Mouse per kg×1/12 (Freireich, et al., (1966) CancerChemother Rep. 50: 219-244). Doses can also be given in milligrams persquare meter of body surface area because this method rather than bodyweight achieves a good correlation to certain metabolic and excretionaryfunctions. Moreover, body surface area can be used as a commondenominator for drug dosage in adults and children as well as indifferent animal species as described by Freireich, et al. (Freireich etal., (1966) Cancer Chemother Rep. 50:219-244). Briefly, to express amg/kg dose in any given species as the equivalent mg/sq m dose, multiplythe dose by the appropriate kg factor. In an adult human, 100 mg/kg isequivalent to 100 mg/kg×37 kg/sq m=3700 mg/m².

Suitable methods for administering a therapeutic composition inaccordance with the methods of the presently-disclosed subject matterinclude, but are not limited to, systemic administration, parenteraladministration (including intravascular, intramuscular, and/orintraarterial administration), oral delivery, buccal delivery, rectaldelivery, subcutaneous administration, intraperitoneal administration,inhalation, dermally (e.g., topical application), intratrachealinstallation, surgical implantation, transdermal delivery, localinjection, intranasal delivery, and hyper-velocityinjection/bombardment. Where applicable, continuous infusion can enhancedrug accumulation at a target site (see, e.g., U.S. Pat. No. 6,180,082).In some embodiments of the therapeutic methods described herein, thetherapeutic compositions are administered orally, intravenously,intranasally, or intraperitoneally to thereby treat a disease ordisorder.

Regardless of the route of administration, the compositions of thepresently-disclosed subject matter typically not only include aneffective amount of a therapeutic agent, but are typically administeredin amount effective to achieve the desired response. As such, the term“effective amount” is used herein to refer to an amount of thetherapeutic composition (e.g., a microvesicle encapsulating atherapeutic agent, and a pharmaceutically vehicle, carrier, orexcipient) sufficient to produce a measurable biological response (e.g.,a decrease in inflammation). Actual dosage levels of active ingredientsin a therapeutic composition of the present invention can be varied soas to administer an amount of the active compound(s) that is effectiveto achieve the desired therapeutic response for a particular subjectand/or application. Of course, the effective amount in any particularcase will depend upon a variety of factors including the activity of thetherapeutic composition, formulation, the route of administration,combination with other drugs or treatments, severity of the conditionbeing treated, and the physical condition and prior medical history ofthe subject being treated. Preferably, a minimal dose is administered,and the dose is escalated in the absence of dose-limiting toxicity to aminimally effective amount. Determination and adjustment of atherapeutically effective dose, as well as evaluation of when and how tomake such adjustments, are known to those of ordinary skill in the art.

For additional guidance regarding formulation and dose, see U.S. Pat.Nos. 5,326,902; 5,234,933; PCT International Publication No. WO93/25521; Berkow et al., (1997) The Merck Manual of Medical Information,Home ed. Merck Research Laboratories, Whitehouse Station, N.J.; Goodmanet al., (1996) Goodman & Gilman's the Pharmacological Basis ofTherapeutics, 9th ed. McGraw-Hill Health Professions Division, New York;Ebadi, (1998) CRC Desk Reference of Clinical Pharmacology. CRC Press,Boca Raton, Fla.; Katzung, (2001) Basic & Clinical Pharmacology, 8th ed.Lange Medical Books/McGraw-Hill Medical Pub. Division, New York;Remington et al., (1975) Remington's Pharmaceutical Sciences, 15th ed.Mack Pub. Co., Easton, Pa.; and Speight et al., (1997) Avery's DrugTreatment: A Guide to the Properties, Choice, Therapeutic Use andEconomic Value of Drugs in Disease Management, 4th ed. AdisInternational, Auckland/Philadelphia; Duch et al., (1998) Toxicol. Lett.100-101:255-263.

With further respect to the therapeutic methods described herein,included the above-described methods of modifying an immune response, insome embodiments of the therapeutic methods, administering amilk-derived microvesicle composition of the presently-disclosed subjectmatter reduces an amount of an inflammatory cytokine in a subject. Insome embodiments, the inflammatory cytokine can be interleukin-1β(IL-1β), tumor necrosis factor-alpha (TNF-α), interferon-y (IFN-γ), orinterleukin-6 (IL-6). In some embodiments, administering the compositionreduces an amount of NF-κB signaling in a subject.

Various methods known to those skilled in the art can be used todetermine a reduction in the amount of inflammatory cytokines or anamount of NF-κB signaling in a subject. For example, in certainembodiments, the amounts of expression of an inflammatory cytokine in asubject can be determined by probing for mRNA of the gene encoding theinflammatory cytokine in a biological sample obtained from the subject(e.g., a tissue sample, a urine sample, a saliva sample, a blood sample,a serum sample, a plasma sample, or sub-fractions thereof) using any RNAidentification assay known to those skilled in the art. Briefly, RNA canbe extracted from the sample, amplified, converted to cDNA, labeled, andallowed to hybridize with probes of a known sequence, such as known RNAhybridization probes immobilized on a substrate, e.g., array, ormicroarray, or quantitated by real time PCR (e.g., quantitativereal-time PCR, such as available from Bio-Rad Laboratories, Hercules,Calif.). Because the probes to which the nucleic acid molecules of thesample are bound are known, the molecules in the sample can beidentified. In this regard, DNA probes for one or more of the mRNAsencoded by the inflammatory genes can be immobilized on a substrate andprovided for use in practicing a method in accordance with thepresently-disclosed subject matter.

With further regard to determining levels of inflammatory cytokines orNF-κB signaling in samples, mass spectrometry and/or immunoassay devicesand methods can also be used to measure the inflammatory cytokines insamples, although other methods can also be used and are well known tothose skilled in the art. See, e.g., U.S. Pat. Nos. 6,143,576;6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615;5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792,each of which is hereby incorporated by reference in its entirety.Immunoassay devices and methods can utilize labeled molecules in varioussandwich, competitive, or non-competitive assay formats, to generate asignal that is related to the presence or amount of an analyte ofinterest. Additionally, certain methods and devices, such as biosensorsand optical immunoassays, can be employed to determine the presence oramount of analytes without the need for a labeled molecule. See, e.g.,U.S. Pat. Nos. 5,631,171; and 5,955,377, each of which is herebyincorporated by reference in its entirety.

Any suitable immunoassay can be utilized, for example, enzyme-linkedimmunoassays (ELISA), radioimmunoassays (RIAs), competitive bindingassays, and the like. Specific immunological binding of the antibody tothe inflammatory molecule can be detected directly or indirectly. Directlabels include fluorescent or luminescent tags, metals, dyes,radionucleotides, and the like, attached to the antibody. Indirectlabels include various enzymes well known in the art, such as alkalinephosphatase, horseradish peroxidase and the like.

The use of immobilized antibodies or fragments thereof specific for theinflammatory molecules is also contemplated by the present invention.The antibodies can be immobilized onto a variety of solid supports, suchas magnetic or chromatographic matrix particles, the surface of an assayplate (such as microtiter wells), pieces of a solid substrate material(such as plastic, nylon, paper), and the like. An assay strip can beprepared by coating the antibody or a plurality of antibodies in anarray on a solid support. This strip can then be dipped into the testbiological sample and then processed quickly through washes anddetection steps to generate a measurable signal, such as for example acolored spot.

Mass spectrometry (MS) analysis can be used, either alone or incombination with other methods (e.g., immunoassays), to determine thepresence and/or quantity of an inflammatory molecule in a subject.Exemplary MS analyses that can be used in accordance with the presentinvention include, but are not limited to: liquid chromatography-massspectrometry (LC-MS); matrix-assisted laser desorption/ionizationtime-of-flight MS analysis (MALDI-TOF-MS), such as for exampledirect-spot MALDI-TOF or liquid chromatography MALDI-TOF massspectrometry analysis; electrospray ionization MS (ESI-MS), such as forexample liquid chromatography (LC) ESI-MS; and surface enhanced laserdesorption/ionization time-of-flight mass spectrometry analysis(SELDI-TOF-MS). Each of these types of MS analysis can be accomplishedusing commercially-available spectrometers, such as, for example, triplequadropole mass spectrometers. Methods for utilizing MS analysis todetect the presence and quantity of peptides, such as inflammatorycytokines, in biological samples are known in the art. See, e.g., U.S.Pat. Nos. 6,925,389; 6,989,100; and 6,890,763 for further guidance, eachof which are incorporated herein by this reference.

With still further regard to the various therapeutic methods describedherein, although certain embodiments of the methods disclosed hereinonly call for a qualitative assessment (e.g., the presence or absence ofthe expression of an inflammatory cytokine in a subject), otherembodiments of the methods call for a quantitative assessment (e.g., anamount of increase in the level of an inflammatory cytokine in asubject). Such quantitative assessments can be made, for example, usingone of the above mentioned methods, as will be understood by thoseskilled in the art.

The skilled artisan will also understand that measuring a reduction inthe amount of a certain feature (e.g., cytokine levels) or animprovement in a certain feature (e.g., inflammation) in a subject is astatistical analysis. For example, a reduction in an amount ofinflammatory cytokines in a subject can be compared to control level ofinflammatory cytokines, and an amount of inflammatory cytokines of lessthan or equal to the control level can be indicative of a reduction inthe amount of inflammatory cytokines, as evidenced by a level ofstatistical significance. Statistical significance is often determinedby comparing two or more populations, and determining a confidenceinterval and/or a p value. See, e.g., Dowdy and Wearden, Statistics forResearch, John Wiley & Sons, New York, 1983, incorporated herein byreference in its entirety. Preferred confidence intervals of the presentsubject matter are 90%, 95%, 97.5%, 98%, 99%, 99.5%, 99.9% and 99.99%,while preferred p values are 0.1, 0.05, 0.025, 0.02, 0.01, 0.005, 0.001,and 0.0001.

Still further provided, in some embodiments, are methods for treating acancer. In some embodiments, a method for treating a cancer is providedthat comprises administering to a subject in need thereof an effectiveamount of an milk-derived microvesicle composition of thepresently-disclosed subject matter (i.e., where the microvesicleencapsulates a therapeutic agent). In some embodiments, the therapeuticagent encapsulated within the microvesicle and used to treat the canceris selected from a phytochemical agent, a chemotherapeutic agent, and anmiRNA molecule, such as those described herein above, as such agentshave been found to be particularly useful in the treatment of cancer.

As used herein, the terms “treatment” or “treating” relate to anytreatment of a condition of interest (e.g., an inflammatory disorder ora cancer), including but not limited to prophylactic treatment andtherapeutic treatment. As such, the terms “treatment” or “treating”include, but are not limited to: preventing a condition of interest orthe development of a condition of interest; inhibiting the progressionof a condition of interest; arresting or preventing the furtherdevelopment of a condition of interest; reducing the severity of acondition of interest; ameliorating or relieving symptoms associatedwith a condition of interest; and causing a regression of a condition ofinterest or one or more of the symptoms associated with a condition ofinterest.

As further non-limiting examples of the treatment of a cancer by acomposition described herein, treating a cancer can include, but is notlimited to, killing cancer cells, inhibiting the development of cancercells, inducing apoptosis in cancer cells, reducing the growth rate ofcancer cells, reducing the incidence or number of metastases, reducingtumor size, inhibiting tumor growth, reducing the available blood supplyto a tumor or cancer cells, promoting an immune response against a tumoror cancer cells, reducing or inhibiting the initiation or progression ofa cancer, increasing the lifespan of a subject with a cancer, orinhibiting or reducing the formation of DNA adducts by chemicalcarcinogens.

In some embodiments of the presently-disclosed subject matter, a methodfor treating a cancer is provided wherein the treating comprisesinhibiting or reducing the formation of DNA adducts. The formation ofDNA adducts (i.e. carcinogens covalently bound to DNA) is widelyconsidered a prerequisite for the initiation and progression of cancerdevelopment. Many carcinogens are known to induce the formation of DNAadducts (Hemminki, 1993) and the presence of DNA adducts in humans hasbeen strongly correlated with an increased risk for cancer development(Santella, 1997). For example, human studies have shown a higheraccumulation of tissue DNA adducts in cigarette smokers than innon-smokers or individuals who have never smoked, indicating that DNAadduct formation is a viable target for the treatment of cancer.

As used herein, the term “cancer” refers to all types of cancer orneoplasm or malignant tumors found in animals, including leukemias,carcinomas, melanoma, and sarcomas. By “leukemia” is meant broadlyprogressive, malignant diseases of the blood-forming organs and isgenerally characterized by a distorted proliferation and development ofleukocytes and their precursors in the blood and bone marrow. Leukemiadiseases include, for example, acute nonlymphocytic leukemia, chroniclymphocytic leukemia, acute granulocytic leukemia, chronic granulocyticleukemia, acute promyelocytic leukemia, adult T-cell leukemia, aleukemicleukemia, a leukocythemic leukemia, basophylic leukemia, blast cellleukemia, bovine leukemia, chronic myelocytic leukemia, leukemia cutis,embryonal leukemia, eosinophilic leukemia, Gross' leukemia, hairy-cellleukemia, hemoblastic leukemia, hemocytoblastic leukemia, histiocyticleukemia, stem cell leukemia, acute monocytic leukemia, leukopenicleukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocyticleukemia, lymphogenous leukemia, lymphoid leukemia, lymphosarcoma cellleukemia, mast cell leukemia, megakaryocytic leukemia, micromyeloblasticleukemia, monocytic leukemia, myeloblastic leukemia, myelocyticleukemia, myeloid granulocytic leukemia, myelomonocytic leukemia,Naegeli leukemia, plasma cell leukemia, plasmacytic leukemia,promyelocytic leukemia, Rieder cell leukemia, Schilling's leukemia, stemcell leukemia, subleukemic leukemia, and undifferentiated cell leukemia.

The term “carcinoma” refers to a malignant new growth made up ofepithelial cells tending to infiltrate the surrounding tissues and giverise to metastases. Exemplary carcinomas include, for example, acinarcarcinoma, acinous carcinoma, adenocystic carcinoma, adenoid cysticcarcinoma, carcinoma adenomatosum, carcinoma of adrenal cortex, alveolarcarcinoma, alveolar cell carcinoma, basal cell carcinoma, carcinomabasocellulare, basaloid carcinoma, basosquamous cell carcinoma,bronchioalveolar carcinoma, bronchiolar carcinoma, bronchogeniccarcinoma, cerebriform carcinoma, cholangiocellular carcinoma, chorioniccarcinoma, colloid carcinoma, comedo carcinoma, corpus carcinoma,cribriform carcinoma, carcinoma en cuirasse, carcinoma cutaneum,cylindrical carcinoma, cylindrical cell carcinoma, duct carcinoma,carcinoma durum, embryonal carcinoma, encephaloid carcinoma, epiennoidcarcinoma, carcinoma epitheliale adenoides, exophytic carcinoma,carcinoma ex ulcere, carcinoma fibrosum, gelatiniform carcinoma,gelatinous carcinoma, giant cell carcinoma, carcinoma gigantocellulare,glandular carcinoma, granulosa cell carcinoma, hair-matrix carcinoma,hematoid carcinoma, hepatocellular carcinoma, Hurthle cell carcinoma,hyaline carcinoma, hypemephroid carcinoma, infantile embryonalcarcinoma, carcinoma in situ, intraepidermal carcinoma, intraepithelialcarcinoma, Krompecher's carcinoma, Kulchitzky-cell carcinoma, large-cellcarcinoma, lenticular carcinoma, carcinoma lenticulare, lipomatouscarcinoma, lymphoepithelial carcinoma, carcinoma medullare, medullarycarcinoma, melanotic carcinoma, carcinoma molle, mucinous carcinoma,carcinoma muciparum, carcinoma mucocellulare, mucoepidermoid carcinoma,carcinoma mucosum, mucous carcinoma, carcinoma myxomatodes,nasopharyngeal carcinoma, oat cell carcinoma, carcinoma ossificans,osteoid carcinoma, papillary carcinoma, periportal carcinoma,preinvasive carcinoma, prickle cell carcinoma, pultaceous carcinoma,renal cell carcinoma of kidney, reserve cell carcinoma, carcinomasarcomatodes, schneiderian carcinoma, scirrhous carcinoma, carcinomascroti, signet-ring cell carcinoma, carcinoma simplex, small-cellcarcinoma, solanoid carcinoma, spheroidal cell carcinoma, spindle cellcarcinoma, carcinoma spongiosum, squamous carcinoma, squamous cellcarcinoma, string carcinoma, carcinoma telangiectaticum, carcinomatelangiectodes, transitional cell carcinoma, carcinoma tuberosum,tuberous carcinoma, verrucous carcinoma, and carcinoma villosum.

The term “sarcoma” generally refers to a tumor which is made up of asubstance like the embryonic connective tissue and is generally composedof closely packed cells embedded in a fibrillar or homogeneoussubstance. Sarcomas include, for example, chondrosarcoma, fibrosarcoma,lymphosarcoma, melanosarcoma, myxosarcoma, osteosarcoma, Abemethy'ssarcoma, adipose sarcoma, liposarcoma, alveolar soft part sarcoma,ameloblastic sarcoma, botryoid sarcoma, chloroma sarcoma, choriocarcinoma, embryonal sarcoma, Wilns' tumor sarcoma, endometrial sarcoma,stromal sarcoma, Ewing's sarcoma, fascial sarcoma, fibroblastic sarcoma,giant cell sarcoma, granulocytic sarcoma, Hodgkin's sarcoma, idiopathicmultiple pigmented hemorrhagic sarcoma, immunoblastic sarcoma of Bcells, lymphoma, immunoblastic sarcoma of T-cells, Jensen's sarcoma,Kaposi's sarcoma, Kupffer cell sarcoma, angiosarcoma, leukosarcoma,malignant mesenchymoma sarcoma, parosteal sarcoma, reticulocyticsarcoma, Rous sarcoma, serocystic sarcoma, synovial sarcoma, andtelangiectaltic sarcoma.

The term “melanoma” is taken to mean a tumor arising from themelanocytic system of the skin and other organs. Melanomas include, forexample, acral-lentiginous melanoma, amelanotic melanoma, benignjuvenile melanoma, Cloudman's melanoma, S91 melanoma, Harding-Passeymelanoma, juvenile melanoma, lentigo maligna melanoma, malignantmelanoma, nodular melanoma subungal melanoma, and superficial spreadingmelanoma.

Additional cancers include, for example, Hodgkin's Disease,Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, breast cancer,ovarian cancer, lung cancer, rhabdomyosarcoma, primary thrombocytosis,primary macroglobulinemia, small-cell lung tumors, primary brain tumors,stomach cancer, colon cancer, malignant pancreatic insulanoma, malignantcarcinoid, premalignant skin lesions, testicular cancer, lymphomas,thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tractcancer, malignant hypercalcemia, cervical cancer, endometrial cancer,and adrenal cortical cancer. In some embodiments, the cancer is selectedfrom the group consisting of breast cancer, uterine cancer, lung cancer,prostate cancer, ovarian cancer, cervical cancer, and pancreatic cancer.

In some embodiments, the compositions of the presently-disclosed subjectmatter can further be used in a method of treating an inflammatorydisorder that includes administering an effective amount of thecomposition to a subject in need of treatment for an inflammatorydisorder. As used herein, the term “inflammatory disorder” includesdiseases or disorders which are caused, at least in part, orexacerbated, by inflammation, which is generally characterized byincreased blood flow, edema, activation of immune cells (e.g.,proliferation, cytokine production, or enhanced phagocytosis), heat,redness, swelling, pain and/or loss of function in the affected tissueor organ. The cause of inflammation can be due to physical damage,chemical substances, micro-organisms, tissue necrosis, cancer, or otheragents or conditions.

Inflammatory disorders include acute inflammatory disorders, chronicinflammatory disorders, and recurrent inflammatory disorders. Acuteinflammatory disorders are generally of relatively short duration, andlast for from about a few minutes to about one to two days, althoughthey can last several weeks. Characteristics of acute inflammatorydisorders include increased blood flow, exudation of fluid and plasmaproteins (edema) and emigration of leukocytes, such as neutrophils.Chronic inflammatory disorders, generally, are of longer duration, e.g.,weeks to months to years or longer, and are associated histologicallywith the presence of lymphocytes and macrophages and with proliferationof blood vessels and connective tissue. Recurrent inflammatory disordersinclude disorders which recur after a period of time or which haveperiodic episodes. Some inflammatory disorders fall within one or morecategories. Exemplary inflammatory disorders include, but are notlimited to atherosclerosis; arthritis; inflammation-promoted cancers;asthma; autoimmune uveitis; adoptive immune response; dermatitis;multiple sclerosis; diabetic complications; osteoporosis; Alzheimer'sdisease; cerebral malaria; hemorrhagic fever; autoimmune disorders; andinflammatory bowel disease.

In yet further embodiments of the presently-disclosed subject matter,the compositions can be used to treat degenerative diseases, such asAlzheimer's disease or Parkinson's disease. In other embodiments, thecompositions can be used to treat diabetes.

As reflected herein above, the compositions and methods of thepresently-disclosed subject matter thus provide the capability of usingmilk-derived microvesicles as a carrier for both natural and syntheticchemopreventive and chemotherapeutic agents. Furthermore, by using themicrovesicles as a carrier, the compositions and methods provide a meansto enhance oral bioavailability of the encapsulated agents by minimizingdestruction of the agent in the gut and liver first-pass effect and alsoa means to improve agent delivery across the blood brain barrier (BBB).Additionally, the compositions and methods described herein provide theadded benefits of using the compositions to: improve the immune systemin cancer patients undergoing chemotherapy; provide naturalcompound-loaded milk and colostrum exosomes as adjuvant therapy toincrease efficacy of chemo-drugs; provide natural product-loaded milkand colostrum exosomes as preventive therapies post-chemotherapy toprevent or delay relapse or recurrence of secondary cancer; supplementcommercial milk formula with exosomes derived from mother's milk orcow's milk/colostrum; boost the immune system of infants and adults bymilk exosomes utilizing the in-built immune factors; improve the immunesystem in subjects with inflammatory disease and viral infectionsincluding common cold since immune system is compromised severely inthese subjects; and increase the solubility and stability of thetherapeutic agents, including the solubility and stability of the agentswithin subjects.

As used herein, the term “subject” includes both human and animalsubjects. Thus, veterinary therapeutic uses are provided in accordancewith the presently disclosed subject matter. As such, thepresently-disclosed subject matter provides for the treatment of mammalssuch as humans, as well as those mammals of importance due to beingendangered, such as Siberian tigers; of economic importance, such asanimals raised on farms for consumption by humans; and/or animals ofsocial importance to humans, such as animals kept as pets or in zoos.Examples of such animals include but are not limited to: carnivores suchas cats and dogs; swine, including pigs, hogs, and wild boars; ruminantsand/or ungulates such as cattle, oxen, sheep, giraffes, deer, goats,bison, and camels; and horses. Also provided is the treatment of birds,including the treatment of those kinds of birds that are endangeredand/or kept in zoos, as well as fowl, and more particularly domesticatedfowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guineafowl, and the like, as they are also of economic importance to humans.Thus, also provided is the treatment of livestock, including, but notlimited to, domesticated swine, ruminants, ungulates, horses (includingrace horses), poultry, and the like.

The practice of the presently-disclosed subject matter can employ,unless otherwise indicated, conventional techniques of cell biology,cell culture, molecular biology, transgenic biology, microbiology,recombinant DNA, and immunology, which are within the skill of the art.Such techniques are explained fully in the literature. See e.g.,Molecular Cloning A Laboratory Manual (1989), 2nd Ed., ed. by Sambrook,Fritsch and Maniatis, eds., Cold Spring Harbor Laboratory Press,Chapters 16 and 17; U.S. Pat. No. 4,683,195; DNA Cloning, Volumes I andII, Glover, ed., 1985; Oligonucleotide Synthesis, M. J. Gait, ed., 1984;Nucleic Acid Hybridization, D. Hames & S. J. Higgins, eds., 1984;Transcription and Translation, B. D. Hames & S. J. Higgins, eds., 1984;Culture Of Animal Cells, R. I. Freshney, Alan R. Liss, Inc., 1987;Immobilized Cells And Enzymes, IRL Press, 1986; Perbal (1984), APractical Guide To Molecular Cloning; See Methods In Enzymology(Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells,J. H. Miller and M. P. Calos, eds., Cold Spring Harbor Laboratory, 1987;Methods In Enzymology, Vols. 154 and 155, Wu et al., eds., AcademicPress Inc., N.Y.; Immunochemical Methods In Cell And Molecular Biology(Mayer and Walker, eds., Academic Press, London, 1987; Handbook OfExperimental Immunology, Volumes I-IV, D. M. Weir and C. C. Blackwell,eds., 1986.

The presently-disclosed subject matter is further illustrated by thefollowing specific but non-limiting examples.

EXAMPLES Example 1 Isolation and Storage of Milk-Derived Exosomes

Numerous centrifugation protocols were assessed using raw bovine milk,and isolated exosomes were measured for their protein content, yield,and their sizes using a NanoSight Nanoparticle Tracking Instrument(Malvern Instruments, Westborough, Mass.). In one preferred procedure, asequential centrifugation of raw milk or colostrum was employed thatincluded centrifugation at 20,000×g at 4° C. for 30 min, 100,000×g at 4°C. for 60 min and 120,000×g at 4° C. for 90 min. Those conditionsyielded, on average, greater than 300 mg exosomal protein/100 ml milk(Tables II and III) and yielded exosomes that were 30-100 nm size asassessed by NanoSight (FIGS. 1-4). Several gallons of raw milk weresubsequently processed and it was found that milk exosomes were isolatedin tens and hundreds gram quantities or could be isolated in kilogramquantities, if desired. Additionally, it was found that exosomesisolated from bovine colostrum resulted in 1.5-fold higher yields ofexosomes than raw bovine milk. In this regard, and without wishing to bebound by any particular theory, it was believed that since colostrumcontained higher levels of immune-related miRNAs than milk, colostrumexosomes could render a higher immune response or modulation than rawmature milk-derived exosomes. Reproducibility was also established inseveral preparations of exosomes made from both bovine milk andcolostrum.

TABLE II Yield of exosomes isolated from bovine mature milk andcolostrum. Weight of pellet Exosomal protein Experiment (g)/100 ml milk(mg)/100 ml milk Exp # 1 2.7 302 Exp # 2 2.5 365 Exp # 3 2.3 265 Exp # 42.6 295 Exp # 5 — 343 Average ± SD 2.53 ± 0.17 314 ± 39

TABLE III Dry mass in milk exosomal pellet. Sample No. Pellet wt. (wet)Pellet wt. (Dry) % Dry wt. Sample No. 1 3.02 0.71 23.5 Sample No. 2 2.750.65 23.7 Sample No. 3 2.96 0.72 24.4 Sample No. 4 2.48 0.60 24.2Average ± SD 2.8 ± 0.2 0.67 ± 0.06 23.95 ± 0.4

Storage of exosomes was analyzed to identify conditions for minimizingcoagulation. Systematic efforts showed that the milk-derived exosomes ifstored at −80° C. at less than or equal to 6 mg exosomal protein/ml PBSremained largely free of coagulated particles, and were observed to bestable in terms of their biological activity and size for months.Similar results were also observed when stored in liquid nitrogen and in50% glycerol at −80° C. Moreover, conversion of milk exosomes to drypowder by Buchi Nano Spray (BÜCHI Labortechnik AG, Switzerland) dryingshowed no change in the particle size and minimal loss of biologicactivity (see, e.g., FIG. 9)

Example 2 Milk and Colostrum Exosomes as Drug Carrier

Several procedures were developed to load therapeutic agents onto themilk- or colostrum-derived exosomes. Those procedures included i)suspending therapeutic agents in PEG-400, mixing with milk-derivedexosomes, followed by low-speed centrifugation; ii) dissolvingtherapeutic agents in ethanol, mixing with milk- or colostrum-derivedexosomes, low-speed centrifugation (10,000×g) to remove unboundtherapeutic agent, and finally high-speed centrifugation; and iii)mixing therapeutic agents in ethanol with 100,000 whey (obtained afterthe 100,000×g centrifugation), low-speed centrifugation and finally120,000×g centrifugation. In one preferred embodiment, incubation ofexosomes in PBS with test agents in the presence of 10% ethanol or 10%ethanol:acetonitrile (1:1) allowed for increased loading of therapeuticagents into the exosomes. The agents utilized in those studies includedcurcumin, withaferin A, demethoxycurcumin, delphinidin, cyanidin, anative mixture of (five) anthocyanidins from bilberry, punicalagin, andtanshinone II. The chemotherapeutic agents doxorubicin, paclitaxel, anddocetaxel were also loaded in the exosomes. In this regard, it wasobserved that the exosomes accepted both hydrophobic (paclitaxel,docetaxel, curcumin, withaferin A, tanshinone II) and hydrophilic agents(berry anthocyanidins, punicalagin) with a loading efficiency of 4% to65% with respect to exosomal proteins, as determined by measurement ofthe drug and exosomal protein contents (Tables IV and V). Sucrosedensity gradient ultracentrifugation confirmed the presence of drugsembedded in the exosomes (FIGS. 5-8). When tested for in vitro releaseusing dialysis tubes against buffer containing the surfactant, Tween-80[47] at 37° C., PAC and WFA were released time-dependently—20%, 43% and70% PAC in 2, 6 and 19 h, and 12%, 40% and 58% WFA in 1, 4, and 24 h,respectively (FIGS. 10, 11A, and 11B). Similarly, the berryanthocyanidins were found to be released time-dependently—20%, 43% and70% in 2, 6 and 19 h, respectively, with SD of less than 10%. Further,the anthocyanidins extracted from the residual material showed the sameUV spectral profile as the starting material indicating that thecompounds were stable in the exosomal formulation.

TABLE IV Dose-dependent loading of bovine milk-derived exosomes withlipophilic (withaferin A) and hydrophilic (anthocyanidins)chemopreventive agents. Amount used (mg) % Drug Chemopreventive Sample #Agent Exosomal protein load Withaferin A A 5 50 3.8 B 10 50 8.6 C 20 5031.4 D 25 50 44.8 Anthocyanidins A 3 30 3.4 B 6 30 9.2 C 8 30 23.0 D 1030 25.1

TABLE V Dose-depended loading of bovine milk-derived exosomes withchemotherapeutic drugs, paclitaxel and docetaxel. ChemotherapeuticAmount used (mg) % Drug agents Sample # Chemo. drug Exosomal proteinload Paclitaxel A 3 30 15.7 B 6 30 20.3 C 9 30 14.9 D 12 30 36.6 E 18 3064.6 Docetaxel A 3 30 6.0 B 6 30 17.7 C 9 30 34.5 D 12 30 49.1 E 18 3055.1

Example 3 Uptake of Milk and Colostrum Exosomes by Human Cancer Cells

To analyze whether exosomes derived from milk or colostrum would besufficiently taken up by cells, including cancer cells, exosomes labeledwith a fluorescent marker were incubated with human cancer cells invitro under standard cell culture conditions. Briefly, milk- andcolostrum-derived exosomes 500 μg (6 mg/ml protein) were incubated withPKH67 solution in Diluent C (final concentration during labeling:5×10⁶M) and incubated for 3 min to ensure homogeneous staining. Thelabeling step was stopped by the addition of an equal volume of FBS for1 min, followed by an equal volume of complete DMEM medium. Labeledexosomes were washed with PBS using a molecular cutoff filter (100,000MWCO), and the exosomes were re-suspended in 100 μl of FBS. Exosomeslabeled with PKH67 were incubated with H1299 lung cancer cells at 37° C.for 4 hrs. After washing three times with PBS, cells were fixed andstained with alexa flour-phalloidin 549 to detect actin filaments andDAPI for the nucleus of the H1299 cells. Upon analysis of the results,it was observed that milk- and colostrum-derived exosomes labeled withthe green fluorescent cell linker (PKH-67) were efficiently incorporatedinto human lung cancer H1299 cells in cell culture (FIG. 12), withmaximal incorporation occurring after 4 to 8 hrs (FIG. 14). It wasfurther observed that siRNA molecules could be efficiently loaded intomilk-exosomes by electroporation, and that such siRNA-loaded exosomescould be used to transfect the H1299 human lung cancer cells (FIG. 15).Additionally, the effect of endocytosis inhibitors in the uptake of theexosomes was assessed by treating H1299 human lung cancer cells withendocytosis inhibitors for 2 hrs prior to incubation of the cells withPKH-26 labeled exosomes. It was subsequently observed that inhibitors ofcaveolae-mediated endocytosis, inhibitors of calthrin-mediatedendocytosis, inhibitors of microtubule trafficking, and metabolicinhibitors each reduced uptake of the milk- and colostrum-derivedexosomes (FIG. 13).

Example 4 Effect of Therapeutic Agent-Loaded Milk- and Colostrum-DerivedExosomes on the Growth of Human Cancer Cells

Anti-proliferative effects of curcumin-, bilberry anthocyanidins-, orwithaferin A-loaded milk exosomes were tested against lung, breast,cervical, ovarian, prostate, and pancreatic cancer cells. In particular,dose-response curves were generated to assess the anti-proliferativeeffect of curcumin-loaded milk exosomes on human lung cancer A549 andH1299 cells (FIG. 16) bilberry anthocyanidins-loaded milk exosomes onhuman lung cancer A549 and H1299 cells (FIG. 17), withaferin A-loadedmilk exosomes on human lung cancer A549 and H1299 cells (FIG. 18),curcumin-loaded milk exosomes on human breast cancer T47D and MDA-MB-231cells (FIG. 19), withaferin A-loaded milk exosomes on human breastcancer T47D and MDA-MB-231 cells (FIG. 20), curcumin-loaded milkexosomes in human uterine cervical cancer (HeLa) cells (FIG. 21),withaferin A-loaded milk exosomes on cisplatin-resistant ovarian cancerOVCA 432 cells (FIG. 22), withaferin A-loaded milk exosomes onpaclitaxel-resistant prostate cancer DU145R cells (FIG. 23), bilberryanthocyanidins-loaded milk exosomes on prostate DU145 and PC3 cancercells (FIG. 24), and bilberry anthocyanidins-loaded milk exosomes onpancreatic MIA PaCa2 and S2013 cancer cells (FIG. 25). Upon analysis ofthe results, it was observed that the therapeutic agent-loaded milkexosomes exhibited significantly higher anti-proliferative activity whencompared to the effect of the free therapeutic agents on the cancercells tested, with the activity being more prominent at lower drugconcentrations. Additionally, it was observed that colostrum-derivedexosomes loaded with therapeutic agent had similar effects in humanlung, breast, and uterine cervical cancer cells (FIG. 27). Greateranti-proliferative activity was observed when exosomal concentration waskept constant and the therapeutic agent concentration varied, implyingsome intrinsic protective effects of the exosomes. Unexpectedly,exosomes from both milk and colostrum alone showed potent inhibition oflung, cervical, and breast cancer cell growth, indicating the presenceof cancer-killing factors (e.g., miRNAs) in those particles (FIG. 26).

Example 5 Biodistribution of Exosomes

To examine the biodistribution of milk-derived exosomes in wholeanimals, evidence of uptake and tissue distribution was obtained bylabeling milk exosomes with a near-IR fluorescent label, DiR (LifeTechnologies, Carlsbad, Calif.), and treating female nude mice with asingle dose of the exosomes administered by oral gavage, intravenously,intranasally, or intraperitoneally (2 mg Exo protein/mouse). Imaging(Biospace lab Photon Imager Optima) of the live animals showed a strongfluorescent signal, with the signal being detected even after 4 d.Harvesting of various organs following euthanasia and imaging showedthat the oral gavage (FIG. 28), intravenous (FIG. 29), intranasal (FIG.30), and intraperitoneal (FIG. 31) routes resulted in similar tissuedistribution of the exosomes, with the exceptions that, with intravenousand intraperitoneal administration, the liver was the predominant siteof distribution, and that, when intransal administration was used, thelung was the predominant site. These data indicate that various routesof administration could be utilized effectively for the delivery of theexosomes and for the selection of target organs.

Example 6 Tissues Therapeutic Agent Levels Following Administration ofTherapeutic Agent-Loaded Milk Exosomes

To determine drug distribution delivered via the milk exosomes, femaleSprague Dawley rats (7 to 8 weeks old) were treated on alternate days bygavage with milk exosomes loaded with curcumin as a model compound (25mg Exo protein/kg/dose; drug load 10%), or equivalent amount of freecurcumin. Two weeks later animals were euthanized and curcumin levelswere measured by solvent extraction and UPLC. Data showed 3-5 timeshigher levels in the lung, liver and brain with the exosomal formulationcompared with free curcumin (FIG. 32). The higher brain curcumin levelswith exosomal formulation can be either due to sheltering of curcuminwithin exosomes, thus minimizing its metabolism, or that the exosomalformulation crossed the blood brain barrier more readily compared tofree curcumin, or both. The higher levels of curcumin in the liver andlung are more likely to be due to its curtailed metabolism.

Example 7 Toxicity of Therapeutic Agent-Loaded Milk Exosomes

To determine potential acute toxicities associated with milk-derivedexosomes, female Sprague Dawley rats were treated with bovinemilk-derived exosomes (5 mg/rat) or vehicle (PBS) intraperitoneally andblood was analyzed for any systemic toxicity 1 hr, 3 hrs, and 6 hrsfollowing administration using an automated AU640® Chemistry Analyzer(Beckman Coulter, Inc., Brea, Calif.) or a Cell-Dyn 3500 hematologyanalyzer by Antech diagnostics (Abbott Laboratories, Santa Clara,Calif.). Upon comparison with the vehicle treatment, the experimentalgroup showed no significant alterations in the liver and kidney functionenzymes (Table VI) or serum proteins (Table VII), as well as nosignificant alterations in hematopoietic parameters Table VIII). Thesedata coupled with lack of inflammatory response (see below) indicatedthat the milk-derived exosomes at the given dose were well tolerated.

TABLE VI Effect on liver enzymes and kidney functions (systemictoxicity) following acute exposure to milk-derived exosomes.Milk-exosomes (5 mg/rat) Biochemical profile Control 1 h 3 h 6 h AST(SGOT) 202.8 ± 49.3  168.3 ± 36.1 264.3 ± 61.6 204.8 ± 43.1 ALT (SGPT)65.3 ± 12.8 56.3 ± 8.7 61.3 ± 6.8  56.8 ± 13.4 Alk Phosphatase  192 ±18.3 151.0 ± 17.4 187.5 ± 50.5 162.3 ± 23.8 GGT 1.3 ± 0.5  3.8 ± 2.2 2.3 ± 1.3  2.8 ± 2.1 Amylase 529.5 ± 107.2 413.5 ± 47.9 423.5 ± 40.1585.5 ± 162  CPK 873.5 ± 238.6  685.5 ± 175.1 1329.0 ± 394.8 915.8 ±388  BUN 19.8 ± 0.5  19.8 ± 2.8 18.8 ± 2.2 17.5 ± 2.6 BUN/CreatinineRatio  36 ± 3.6 44.0 ± 1.8 47.5 ± 4.9 33.5 ± 5.0 Phosphorus 18.4 ± 3.0 13.5 ± 1.2 13.9 ± 1.1 13.1 ± 0.9 Calcium 12.4 ± 1.0  11.9 ± 0.8 12.4 ±0.5 11.7 ± 0.9

TABLE VII Effect on serum proteins and other molecules (systemictoxicity) following acute exposure to milk-derived exosomes.Milk-exosomes (5 mg/rat) Biochemical profile Control 1 h 3 h 6 h TotalProtein 6.9 ± 0.4 6.4 ± 0.2 6.4 ± 0.3 6.5 ± 0.5 Albumin 3.8 ± 0.2 3.7 ±0.2 3.6 ± 0.2 3.7 ± 0.3 Globulin 3.1 ± 0.2 2.8 ± 0.1 2.8 ± 0.2 2.8 ± 0.2A/G Ratio 1.2 ± 0.1 1.3 ± 0.0 1.3 ± 0.1 1.3 ± 0.0 Glucose 193.8 ± 55.8 158.0 ± 13.0  186.5 ± 42.2  208.3 ± 28.6  Cholesterol  94 ± 10.1 101.3 ±9.5  85.8 ± 15.8 81.5 ± 9.3  Triglyceride 134.5 ± 26.6  69.0 ± 18.4 79.8± 16.7 86.0 ± 26.8

TABLE VIII Effect on the hematological parameters (systemic toxicity)following acute exposure to milk-derived exosomes. Milk-exosomes (5mg/rat) Biochemical profile Control 1 h 3 h 6 h WBC  5.7 ± 2.5 6.8 ± 1.05.7 ± 1.0 6.5 ± 1.6 HGB 14.0 ± 1.2 11.2 ± 4.7  13.2 ± 0.6  13.5 ± 0.9 HCT 44.0 ± 3.5 42.3 ± 3.9  41.3 ± 1.9  41.5 ± 3.4  MCV 60.8 ± 1.0 61.0 ±1.2  61.5 ± 1.0  59.0 ± 1.8  MCHC 31.8 ± 0.5 26.4 ± 10.6 32.0 ± 0.9 32.4 ± 1.0  Platelet Count  689.0 ± 145.8 850.0 ± 8.5  465.0 ± 296.0605.8 ± 433.2 Neutrophils 12.0 ± 3.5 15.0 ± 2.8  39.3 ± 27.4 32.7 ± 35.8Lymphocytes 84.5 ± 4.5 48.5 ± 37.6 41.5 ± 36.0 50.8 ± 40.4 AbsoluteNeutrophils  637.3 ± 136.6 495.8 ± 572.7 1702.0 ± 1672.8 1456.0 ± 1747.6Absolute Lymphocytes  4886.5 ± 2252.6 3277.8 ± 2677.6 2453.5 ± 2308.13703.3 ± 3357.8 Absolute Monocytes 102.6 ± 83.6 2816.8 ± 3165.1 1036.0 ±1875.0  960.3 ± 1657.2 Absolute Eosinophils  75.3 ± 29.8 135.5 ± 20.6 107.5 ± 51.3  86.8 ± 72.8

Similar experiments were performed to assess toxicity following chronicexposure to colostrum-derived and milk-derived exosomes and to determinewhether differences in toxicity following the administration ofmilk-derived versus colostrum-derived exosomes. In those experiments,female Sprague-Dawley rats (6-7 weeks old) were provided with controldiet (AIN 93M) or water ad libitum, and were treated with milk- andcolostrum-derived exosomes (5 mg/rat) by oral gavage daily for 15 days.At euthanasia, blood was collected and again analyzed using an automatedAU640® Chemistry Analyzer (Beckman Coulter, Inc., Brea, Calif. USA) or aCell-Dyn 3500 hematology analyzer by Antech diagnostics (Abbottlaboratories, Santa Clara, Calif., USA). Following comparison with thevehicle treatment, neither experimental group showed significantalterations in the liver and kidney function enzymes (Table IX) or serumproteins (Table X), and further showed no significant alterations inhematopoietic parameters (Table XI). Additionally, no significantdifferences were observed between the group administered milk-derivedexosomes and the group administered colostrum-derived exosomes.

TABLE IX Effect on liver enzymes and kidney functions (Systemictoxicity) following chronic exposure to milk- and colostrum-derivedexosomes. Exosomes (5 mg/animal) daily Biochemical test Control MilkColostrum AST (SGOT)  235 ± 85.7 220.5 ± 58.7 223.5 ± 62.8 ALT (SGPT)66.0 ± 3.2 64.2 ± 9.7 65.5 ± 5.5 Alk Phosphatase 243.8 ± 58.9 151.8 ±55.7 183.8 ± 42.8 GGT  5.3 ± 1.0  3.3 ± 1.7  3.5 ± 0.6 Amylase 529.8 ±55.3 496.0 ± 42.9  588.5 ± 123.3 CPK 25.0 ± 0.0 25.0 ± 0.0 25.0 ± 0.0BUN 23.8 ± 3.1 18.8 ± 1.9 22.0 ± 3.7 BUN/Creatinine Ratio  98.8 ± 42.1 65.5 ± 30.3  78.8 ± 34.2 Phosphorus 15.9 ± 1.7 15.1 ± 2.4 15.0 ± 2.5Calcium 10.6 ± 1.1 11.1 ± 1.1 10.8 ± 1.3

TABLE X Effect on serum proteins and other molecules (Systemic toxicity)following chronic exposure to milk- and colostrum-derived exosomes.Exosomes (5 mg/animal) daily Biochemical test Control Milk ColostrumTotal Protein 6.8 ± 0.2 6.7 ± 0.5 6.7 ± 0.4 Albumin 3.9 ± 0.2 4.0 ± 0.33.9 ± 0.3 Globulin 2.9 ± 0.1 2.7 ± 0.2 2.8 ± 0.4 A/G Ratio 1.3 ± 0.1 1.5± 0.1 1.5 ± 0.2 Glucose 205.5 ± 31.0  193.5 ± 34.8  183.3 ± 21.1 Cholesterol 105.8 ± 14.6  105.5 ± 12.9  96.5 ± 10.2 Triglyceride 117.3 ±9.4  69.3 ± 13.8 59.0 ± 24.2

TABLE XI Effect on the hematological parameters (Systemic toxicity)following chronic exposure to milk-derived exosomes. Exosomes (5mg/animal) daily Biochemical test Control Milk Colostrum WBC 5.7 ± 1.7 7.0 ± 2.0 6.8 ± 1.7 HGB 14.0 ± 0.3  13.8 ± 0.6 13.8 ± 1.1  HCT 43.3 ±2.1  42.3 ± 1.9 42.7 ± 3.8  MCV 45.5 ± 29.0 59.3 ± 1.7 58.7 ± 2.1  MCHC32.3 ± 2.3  32.8 ± 0.5 32.3 ± 0.6  Platelet Count 755.7 ± 134.9 772.8 ±85.8 883.3 ± 266.0 Neutrophils 11.5 ± 3.0  13.5 ± 8.4 15.3 ± 3.6 Lymphocytes 86.0 ± 2.8  81.0 ± 7.4 80.8 ± 2.2  Absolute Neutrophils668.5 ± 324.6  883.0 ± 422.2 995.8 ± 196.9 Absolute Lymphocytes 4852.0 ±1413.4  5701.5 ± 1881.1 5469.8 ± 1472.6 Absolute Monocytes 61.8 ± 46.2 212.5 ± 115.9 204.0 ± 104.4 Absolute Eosinophils 67.8 ± 55.5 178.0 ±94.6 80.5 ± 93.8

Example 8 Effect of Therapeutic Agent-Loaded Milk- and Colostrum-DerivedExosomes on Inflammatory Markers

To assess the effect of therapeutic agent-loaded milk- andcolostrum-derived exosomes on inflammatory markers, human lung A549cancer cells were initially pre-treated with colostrum-derived exosomes(Exo), curcumin (Cur) or curcumin-loaded colostrum-derived exosomes(Exo-cur) for 6 hrs followed by treatment with or without tumor necrosisfactor (TNF-α) (10 ng/ml) to induce NF-κB activation, and NF-κB levelswere subsequently determined by electrophoretic mobility shift assay(EMSA). Both the colostrum-derived exosomes alone and thecurcumin-loaded colostrum-derived exosomes showed anti-inflammatoryactivity against constitutive and TNF-α induced inflammation (FIG. 33).Colostrum-derived exosomes alone and curcumin-loaded colostrum-derivedexosomes also each exhibited anti-inflammatory activity againstconstitutive and TNF-α induced inflammation in human lung H1299 cancercells (FIG. 34) and in human breast MDA-MB-231 cancer cells (FIG. 35)when those cells were pre-treated with exosomes (Exo), curcumin (Cur) orcurcumin-loaded exosomes (Exo-cur) for 6 hrs followed by treatment withor without tumor necrosis factor TNF-α (10 ng/ml) to induce NF-κBactivation. Colostrum-derived exosomes alone and curcumin-loadedcolostrum-derived exosome also showed modest protection againstlipopolysaccharide (LPS)-induced NF-κB activation in lung A549 and H1299cancer cells (FIG. 36).

Example 9 Milk- and Colostrum-Derived Exosome Markers

Milk- and colostrum-derived exosomes were analyzed for transmembraneprotein markers or transpanins (e.g., CD63 and CD81) by western blotanalysis. Results from those experiments confirmed that the milk- andcolostrum-derived exosomes carried those surface proteins, withsubstantially higher levels of CD63 in colostrum exosomes (FIGS. 37 and38). The presence of select exosomal proteins in both milk- andcolostrum-derived exosomes was also analyzed by RT-PCR (FIG. 39), whichconfirmed that the microvesicles isolated from milk and colostrum wereindeed exosomes. Of the eight immune function-related proteins analyzed,RNA levels showed that 5 proteins were significantly higher in colostrumversus milk-derived exosomes suggesting that colostrum-derived exosomescan, in some instances, serve as a more effective immune booster.Additionally, the presence of immune related miRNAs in colostrum-andmilk-derived exosomes was confirmed by RT-PCR (FIG. 40). Two miRNAsnamely, miR-155 and miR-223 were significantly higher in colostrumcompared to milk-derived exosomes.

Example 10 Acute Immunological Response with Milk Exosomes

To test early immunological response of milk exosomes in vitro, THP-1monocytes were differentiated into macrophages with 100 nM phorbol12-myristate 13-acetate and then treated with milk exosomes at 25 and100 μg/ml or LPS (100 ng/ml) for 1, 3, and 6 hrs and culture mediacollected for cytokine analysis. At 6 hrs (FIG. 41), the resultsindicated significant time-dependent increase in early inflammatoryresponse in cytokines IL-6 and IL-1β (EIA assay, Cayman chemicals) byLPS, with significantly smaller increases observed with milk exosomes,particularly for IL-6, despite relatively high doses (the levels at 1and 3 hrs were still lower).

Anti-inflammatory activity of bovine milk-derived exosomes per se wasalso assessed in human lung H1299 and A549 cells, and it was observedthat the exosomes were capable of inhibiting constitutive and TNF-αinduced NF-κB activation in those cells (FIG. 42). Milk-derived exosomesalso showed modest (30-40%) protection against lipopolysaccharide(LPS)-induced NF-κB in the lung of S/D rats (FIG. 43). Similarprotective observations were made in liver and brain samples. In theabsence of LPS treatment, milk exosomes showed no detectable increase inNF-κB in the lung compared with vehicle treatment, indicating milkexosomes were well tolerated.

Example 11 Anti-Tumor Activity of Therapeutic Agent-loaded Milk-DerivedExosomes

To assess the anti-tumor activity of therapeutic agent-loadedmilk-derived exosomes, nude mice were inoculated with human lung A549cancer cells (3×10⁶ cells). Following inoculation with the human lungA549 cancer cells, when tumor xenografts grew to over 60 mm³, animalswere treated intraperitoneally three times a week with withaferinA-loaded milk exosomes (Exo-WFA, 4 mg/kg WFA and 1.3 mg Exoprotein/mouse). Two other groups were treated intraperitoneally with theexosomes alone (1.3 mg/mouse) or with withaferin A (4 mg/kg). Uponanalysis of the results, it was observed that exosomally-administeredwithaferin A significantly reduced tumor volume when compared to thegroups administered exosomes alone or withaferin A alone (FIG. 44).Similar experiments were conducted to assess the anti-tumor activity ofmilk exosomes loaded with bilberry anthocyanidins in human lung A549cancer cells and it was observed that that exosomally-administeredbilberry anthocyanidins also significantly reduced tumor volume whencompared to the groups administered exosomes alone or bilberryanthocyanidins alone (FIG. 45).

Discussion of Examples 1-11

The results of the studies described herein above showed that i) bulkexosomes can be isolated from both bovine milk and colostrum; ii) theexosomes generally range from 30-100 nm and yield greater than 300 mgexosomal protein per 100 ml milk; iii) milk and colostrum exosomes canbe loaded with a variety of hydrophilic and lipophilic compounds,including chemotherapeutic agents; iv) therapeutic agents embedded inexosomes showed higher anti-proliferative, anti-tumor, andanti-inflammatory activities than free therapeutic agents; and v)exosomes per se (in the absence of therapeutic agent) from both milk andcolostrum showed significant cancer cell killing activity.

Throughout this document, various references are mentioned. All suchreferences are incorporated herein by reference, including thereferences set forth in the following list:

REFERENCES

-   1. Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D.    R., Porter, P. L. and Malone, K. E. (2009). Risk factors for    triple-negative breast cancer in women under the age of 45 years.    Cancer Epidemiol Biomarkers Prey 18, 1157-66.-   2. Onitilo, A. A., Engel, J. M., Greenlee, R. T. and Mukesh, B. N.    (2009). Breast cancer subtypes based on ER/PR and Her2 expression:    comparison of clinicopathologic features and survival. Clin Med Res    7, 4-13.-   3. Escudier, B. et al. (2005). Vaccination of metastatic melanoma    patients with autologous dendritic cell (DC) derived-exosomes:    results of the first phase I clinical trial. J Transl Med 3, 10.-   4. Morse, M. A. et al. (2005). A phase I study of dexosome    immunotherapy in patients with advanced non-small cell lung cancer.    J Transl Med 3, 9.-   5. Sun, D. M. et al. (2010). A Novel Nanoparticle Drug Delivery    System: The Anti-inflammatory Activity of Curcumin Is Enhanced When    Encapsulated in Exosomes. Molecular Therapy 18, 1606-1614.-   6. Matsumoto, G., Namekawa, J., Muta, M., Nakamura, T., Bando, H.,    Tohyama, K., Toi, M. and Umezawa, K. (2005). Targeting of nuclear    factor kappa B pathways by dehydroxymethylepoxyquinomicin, a novel    inhibitor of breast carcinomas: Antitumor and antiangiogenic    potential in vivo. Clinical Cancer Research 11, 1287-1293.-   7. Sunters, A. et al. (2003). FoxO3a transcriptional regulation of    bim controls apoptosis in paclitaxel-treated breast cancer cell    lines. Journal of Biological Chemistry 278, 49795-49805.-   8. Downs-Holmes, C. and Silverman, P. (2011). Breast cancer:    overview & updates. Nurse Pract 36, 20-6; quiz 7.-   9. Dunnwald, L. K., Rossing, M. A. and Li, C. I. (2007). Hormone    receptor status, tumor characteristics, and prognosis: a prospective    cohort of breast cancer patients. Breast Cancer Res 9, R6.-   10. Kausar, H., Jeyabalan, J., Aqil, F., Chabba, D., Sidana, J.,    Singh, I. P. and Gupta, R. C. (2012). Berry anthocyanidins    synergistically suppress growth and invasive potential of human    non-small-cell lung cancer cells. Cancer Lett 325, 54-62.-   11. Kuo, M. T. (2007). Roles of multidrug resistance genes in breast    cancer chemoresistance. Adv Exp Med Biol 608, 23-30.-   12. Siegel, R., Ward, E., Brawley, O. and Jemal, A. (2011). Cancer    statistics, 2011: the impact of eliminating socioeconomic and racial    disparities on premature cancer deaths. CA Cancer J Clin 61, 212-36.-   13. Desantis, C., Ma, J., Bryan, L. and Jemal, A. (2013). Breast    cancer statistics, 2013. CA Cancer J Clin-   14. American_Cancer_Society. Breast Cancer Facts & Figures    2011-2012. In American Cancer Society, Inc. ed.). American Cancer    Society, Atlanta.-   15. Munagala, R., Aqil, F. and Gupta, R. C. (2011). Promising    molecular targeted therapies in breast cancer. Indian J Pharmacol    43, 236-45.-   16. Xiao, H., Verdier-Pinard, P., Fernandez-Fuentes, N., Burd, B.,    Angeletti, R., Fiser, A., Horwitz, S. B. and Orr, G. A. (2006).    Insights into the mechanism of microtubule stabilization by Taxol.    Proc Natl Acad Sci USA 103, 10166-73.-   17. Chun, E. and Lee, K. Y. (2004). Bc1-2 and Bcl-xL are important    for the induction of paclitaxel resistance in human hepatocellular    carcinoma cells. Biochem Biophys Res Commun 315, 771-9.-   18. David, O., Jett, J., LeBeau, H., Dy, G., Hughes, J.,    Friedman, M. and Brody, A. R. (2004). Phospho-Akt overexpression in    non-small cell lung cancer confers significant stage-independent    survival disadvantage. Clinical Cancer Research 10, 6865-71.-   19. Dong, Q. G. et al. (2002). The function of multiple    IkappaB:NF-kappaB complexes in the resistance of cancer cells to    Taxol-induced apoptosis. Oncogene 21, 6510-9.-   20. Yabuki, N., Sakata, K., Yamasaki, T., Terashima, H., Mio, T.,    Miyazaki, Y., Fujii, T. and Kitada, K. (2007). Gene amplification    and expression in lung cancer cells with acquired paclitaxel    resistance. Cancer Genet Cytogenet 173, 1-9.-   21. Monzo, M. et al. (1999). Paclitaxel resistance in non-small-cell    lung cancer associated with beta-tubulin gene mutations. J Clin    Oncol 17, 1786-93.-   22. Ciardiello, F., Caputo, R., Borriello, G., Del Bufalo, D.,    Biroccio, A., Zupi, G., Bianco, A. R. and Tortora, G. (2002). ZD1839    (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances    taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7    ADR human breast cancer cells. Int J Cancer 98, 463-9.-   23. Duan, Z. et al. (2006). Signal transducers and activators of    transcription 3 pathway activation in drug-resistant ovarian cancer.    Clinical Cancer Research 12, 5055-63.-   24. Mine, T. et al. (2009). Breast cancer cells expressing stem cell    markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T    cells. Cancer Immunol Immunother 58, 1185-94.-   25. Wu, C. P., Ohnuma, S. and Ambudkar, S. V. (2011). Discovering    natural product modulators to overcome multidrug resistance in    cancer chemotherapy. Curr Pharm Biotechnol 12, 609-20.-   26. Sun, L. R., Cui, S. X. and Qu, X. J. (2009). Overcoming    Multidrug Resistance in Cancer: An Update on Research of Natural    Products. Drugs of the Future 34, 53-59.-   27. Nabekura, T., Kamiyama, S. and Kitagawa, S. (2005). Effects of    dietary chemopreventive phytochemicals on P-glycoprotein function.    Biochem Biophys Res Commun 327, 866-70.-   28. Kannaiyan, R. et al. (2011). Celastrol inhibits proliferation    and induces chemosensitization through down-regulation of NF-kappa B    and STAT3 regulated gene products in multiple myeloma cells. British    Journal of Pharmacology 164, 1506-1521.-   29. Aisner, J. (2007). Overview of the changing paradigm in cancer    treatment: oral chemotherapy. Am J Health Syst Pharm 64, S4-7.-   30. Joo, K. M., Park, K., Kong, D. S., Song, S. Y., Kim, M. H.,    Lee, G. S., Kim, M. S. and Nam, D. H. (2008). Oral paclitaxel    chemotherapy for brain tumors: ideal combination treatment of    paclitaxel and P-glycoprotein inhibitor. Oncol Rep 19, 17-23.-   31. Yang, F., Jin, C., Jiang, Y., Li, J., Di, Y., Ni, Q. and Fu, D.    (2011). Liposome based delivery systems in pancreatic cancer    treatment: from bench to bedside. Cancer Treat Rev 37, 633-42.-   32. Bansal, S. S., Kausar, H., Aqil, F., Jeyabalan, J., Vadhanam, M.    V., Gupta, R. C. and Ravoori, S. (2011). Curcumin implants for    continuous systemic delivery: safety and biocompatibility. Drug    Deliv. and Transl. Res. 1, 332-341.-   33. Feng, L. and Mumper, R. J. (2013). A critical review of    lipid-based nanoparticles for taxane delivery. Cancer Lett 334,    157-75.-   34. Kooijmans, S. A., Vader, P., van Dommelen, S. M., van    Solinge, W. W. and Schiffelers, R. M. (2012). Exosome mimetics: a    novel class of drug delivery systems. Int J Nanomedicine 7, 1525-41.-   35. Lakhal, S. and Wood, M. J. (2011). Exosome nanotechnology: an    emerging paradigm shift in drug delivery: exploitation of exosome    nanovesicles for systemic in vivo delivery of RNAi heralds new    horizons for drug delivery across biological barriers. Bioessays 33,    737-41.-   36. Aiyer, H. S., Srinivasan, C. and Gupta, R. C. (2008). Dietary    berries and ellagic acid diminish estrogen-mediated mammary    tumorigenesis in ACI rats. Nutr Cancer 60, 227-34.-   37. Ravoori, S., Vadhanam, M. V., Aqil, F. and Gupta, R. C. (2012).    Inhibition of estrogen-mediated mammary tumorigenesis by blueberry    and black raspberry. J Agric Food Chem 60, 5547-55.-   38. Gupta, R. C. et al. (2012). Controlled-release systemic    delivery—a new concept in cancer chemoprevention. Carcinogenesis 33,    1608-15.-   39. Chou, T. C. and Talalay, P. (1984). Quantitative analysis of    dose-effect relationships: the combined effects of multiple drugs or    enzyme inhibitors. Adv Enzyme Regul 22, 27-55.-   40. Stan, S. D., Hahm, E. R., Warin, R. and Singh, S. V. (2008).    Withaferin A causes FOXO3a- and Bim-dependent apoptosis and inhibits    growth of human breast cancer cells in vivo. Cancer Res 68, 7661-9.-   41. Das, K. C. and White, C. W. (1997). Activation of NF-kappa B by    antineoplastic agents—Role of protein kinase C. Journal of    Biological Chemistry 272, 14914-14920.-   42. Aggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S.,    Newman, R. A., Bueso-Ramos, C. E. and Price, J. E. (2005). Curcumin    suppresses the paclitaxel-induced nuclear factor-kappa B pathway in    breast cancer cells and inhibits lung metastasis of human breast    cancer in nude mice. Clinical Cancer Research 11, 7490-7498.-   43. Kaileh, M. et al. (2007). Withaferin a strongly elicits IkappaB    kinase beta hyperphosphorylation concomitant with potent inhibition    of its kinase activity. Journal of Biological Chemistry 282,    4253-64.-   44. Sun, D., Zhuang, X., Zhang, S., Deng, Z. B., Grizzle, W.,    Miller, D. and Zhang, H. G. (2013). Exosomes are endogenous    nanoparticles that can deliver biological information between cells.    Adv Drug Deliv Rev 65, 342-7.-   45. Gill, K. K., Kaddoumi, A. and Nazzal, S. (2012). Mixed micelles    of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of    paclitaxel and parthenolide: enhanced chemosenstization and    antitumor efficacy against non-small cell lung cancer (NSCLC) cell    lines. Eur J Pharm Sci 46, 64-71.-   46. Hogue, M., Dave, S., Gupta, P. and Saleemuddin, M. (2013). Oleic    Acid May Be the Key Contributor in the BAMLET-Induced Erythrocyte    Hemolysis and Tumoricidal Action. PLoS One 8, e68390.-   47. Liskova, K., Kelly, A. L., O'Brien, N. and Brodkorb, A. (2010).    Effect of denaturation of alpha-lactalbumin on the formation of    BAMLET (bovine alpha-lactalbumin made lethal to tumor cells). J    Agric Food Chem 58, 4421-7.-   48. Rammer, P. et al. (2010). BAMLET activates a lysosomal cell    death program in cancer cells. Molecular Cancer Therapeutics 9,    24-32.-   49. Jenkins, D. E., Hornig, Y. S., Oei, Y., Dusich, J. and    Purchio, T. (2005). Bioluminescent human breast cancer cell lines    that permit rapid and sensitive in vivo detection of mammary tumors    and multiple metastases in immune deficient mice. Breast Cancer    Research 7, R444-R454.-   50. Stan, S. D., Zeng, Y. and Singh, S. V. (2008). Ayurvedic    medicine constituent withaferin a causes G2 and M phase cell cycle    arrest in human breast cancer cells. Nutr Cancer 60 Suppl 1, 51-60.-   51. Munagala, R., Kausar, H., Munjal, C. and Gupta, R. C. (2011).    Withaferin A induces p53-dependent apoptosis by repression of HPV    oncogenes and upregulation of tumor suppressor proteins in human    cervical cancer cells. Carcinogenesis 32, 1697-705.-   52. Srinivasan, S., Ranga, R. S., Burikhanov, R., Han, S. S. and    Chendil, D. (2007). Par-4-dependent apoptosis by the dietary    compound withaferin A in prostate cancer cells. Cancer Res 67,    246-53.-   53. Aqil, F., Jeyabalan, J., Kausar, H., Bansal, S. S., Sharma, R.    J., Singh, I. P., Vadhanam, M. V. and Gupta, R. C. (2012).    Multi-layer polymeric implants for sustained release of    chemopreventives. Cancer Lett 326, 33-40.-   54. Yu, Y. et al. (2010). Withaferin A targets heat shock protein 90    in pancreatic cancer cells. Biochem Pharmacol 79, 542-51.-   55. Maitra, R., Porter, M. A., Huang, S. and Gilmour, B. P. (2009).    Inhibition of NFkappaB by the natural product Withaferin A in    cellular models of Cystic Fibrosis inflammation. J Inflamm (Lond) 6,    15.-   56. Killion, J. J., Radinsky, R. and Fidler, I. J. (1998).    Orthotopic models are necessary to predict therapy of transplantable    tumors in mice. Cancer Metastasis Rev 17, 279-84.-   57. Nakayama, S. et al. (2009). Prediction of paclitaxel sensitivity    by CDK1 and CDK2 activity in human breast cancer cells. Breast    Cancer Res 11, R12.-   58. Jenkins, D. E., Oei, Y., Hornig, Y. S., Yu, S. F., Dusich, J.,    Purchio, T. and Contag, P. R. (2003). Bioluminescent imaging (BLI)    to improve and refine traditional murine models of tumor growth and    metastasis. Clin Exp Metastasis 20, 733-744.-   59. Richert, M. M. et al. (2005). Metastasis of hormone-independent    breast cancer to lung and bone is decreased by    alpha-difluoromethylornithine treatment. Breast Cancer Res 7,    R819-27.-   60. Dadiani, M., Kalchenko, V., Yosepovich, A., Margalit, R.,    Hassid, Y., Degani, H. and Seger, D. (2006). Real-time imaging of    lymphogenic metastasis in orthotopic human breast cancer. Cancer Res    66, 8037-41.-   61. Cleator, S., Heller, W. and Coombes, R. C. (2007).    Triple-negative breast cancer: therapeutic options. Lancet Oncol 8,    235-44.-   62. Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U. and    Harbeck, N. (2009). Triple-negative breast cancer—current status and    future directions. Ann Oncol 20, 1913-27.-   63. Kutuk, O. and Letai, A. (2008). Alteration of the mitochondrial    apoptotic pathway is key to acquired paclitaxel resistance and can    be reversed by ABT-737. Cancer Research 68, 7985-7994.-   64. Weigelt, B., Peterse, J. L. and van 't Veer, L. J. (2005).    Breast cancer metastasis: markers and models. Nat Rev Cancer 5,    591-602.-   65. Nakshatri, H., Bhat-Nakshatri, P., Martin, D. A., Goulet, R. J.,    Jr. and Sledge, G. W., Jr. (1997). Constitutive activation of    NF-kappaB during progression of breast cancer to hormone-independent    growth. Mol Cell Biol 17, 3629-39.-   66. Huber, M. A. et al. (2004). NF-kappaB is essential for    epithelial-mesenchymal transition and metastasis in a model of    breast cancer progression. J Clin Invest 114, 569-81.-   67. Das, K. C. and White, C. W. (1997). Activation of NF-kappaB by    antineoplastic agents. Role of protein kinase C. Journal of    Biological Chemistry 272, 14914-20.-   68. Aggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S.,    Newman, R. A., Bueso-Ramos, C. E. and Price, J. E. (2005). Curcumin    suppresses the paclitaxel-induced nuclear factor-kappaB pathway in    breast cancer cells and inhibits lung metastasis of human breast    cancer in nude mice. Clin Cancer Res 11, 7490-8.-   69. Kang, H. J., Lee, S. H., Price, J. E. and Kim, L. S. (2009).    Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in    breast cancer cells and potentiates the growth inhibitory effect of    paclitaxel in a breast cancer nude mice model. Breast J 15, 223-9.-   70. Wang, L., Brugge, J. S. and Janes, K. A. (2011). Intersection of    FOXO- and RUNX1-mediated gene expression programs in single breast    epithelial cells during morphogenesis and tumor progression. Proc    Natl Acad Sci USA 108, E803-12.-   71. Zhang, Y. Q., Gan, B. Y., Liu, D. and Paik, J. H. (2011). FoxO    family members in cancer. Cancer Biology & Therapy 12, 253-259.-   72. Chovolou, Y., Lupertz, R., Pavkovic, M., Kahl, R. and Watjen, W.    (2011). Molecular Effects of FOXO in Human Cancer Cells.    Naunyn-Schmiedebergs Archives of Pharmacology 383, 3-3.-   73. Scalera, F., Dittrich, R., Beckmann, M. W. and Beinder, E.    (2002). Effect of endothelin-1 on intracellular glutathione and    lipid peroxide availability and on the secretion of vasoactive    substances by human umbilical vein endothelial cells. Eur J Clin    Invest 32, 556-62.-   74. Kim, J. S., He, L. and Lemasters, J. J. (2003). Mitochondrial    permeability transition: a common pathway to necrosis and apoptosis.    Biochem Biophys Res Commun 304, 463-70.-   75. Kroemer, G., Galluzzi, L. and Brenner, C. (2007). Mitochondrial    membrane permeabilization in cell death. Physiol Rev 87, 99-163.-   76. Rahn, C. A., Bombick, D. W. and Doolittle, D. J. (1991).    Assessment of mitochondrial membrane potential as an indicator of    cytotoxicity. Fundam Appl Toxicol 16, 435-48.-   77. Ferreira, C. G., Span, S. W., Peters, G. J., Kruyt, F. A. and    Giaccone, G. (2000). Chemotherapy triggers apoptosis in a    caspase-8-dependent and mitochondria-controlled manner in the    non-small cell lung cancer cell line NCI-H460. Cancer Res 60,    7133-41.-   78. Yan, F. et al. (2012). Gambogenic acid induced    mitochondrial-dependent apoptosis and referred to Phospho-Erk1/2 and    Phospho-p38 MAPK in human hepatoma HepG2 cells. Environ Toxicol    Pharmacol 33, 181-90.-   79. Han, L. L., Xie, L. P., Li, L. H., Zhang, X. W., Zhang, R. Q.    and Wang, H. Z. (2009). Reactive oxygen species production and    Bax/Bcl-2 regulation in honokiol-induced apoptosis in human    hepatocellular carcinoma SMMC-7721 cells. Environ Toxicol Pharmacol    28, 97-103.-   80. Pazos, P., Lanari, C., Meiss, R., Charreau, E. H. and    Pasqualini, C. D. (1992). Mammary carcinogenesis induced by    N-methyl-N-nitrosourea (MNU) and medroxyprogesterone acetate (MPA)    in BALB/c mice. Breast Cancer Res Treat 20, 133-8.-   81. Bansal, S. S., Kausar, H., Vadhanam, M. V., Ravoori, S. and    Gupta, R. C. (2011). Controlled systemic delivery by polymeric    implants enhances tissue and plasma curcumin levels compared with    oral administration. European Journal of Pharmaceutics and    Biopharmaceutics-   82. Cao, P. X., Vadhanam, M. V., Spencer, W. A., Cai, J. and    Gupta, R. C. (2011). Sustained Systemic Delivery of Green Tea    Polyphenols by Polymeric Implants Significantly Diminishes    Benzo[a]pyrene-Induced DNA Adducts. Chemical Research in Toxicology    24, 877-886.-   83. Bansal, S. S., Vadhanam, M. V. and Gupta, R. C. (2011).    Development and In Vitro-In Vivo Evaluation of Polymeric Implants    for Continuous Systemic Delivery of Curcumin. Pharmaceutical    Research 28, 1121-1130.-   84. Thaiparambil, J. T. et al. (2011). Withaferin A inhibits breast    cancer invasion and metastasis at sub-cytotoxic doses by inducing    vimentin disassembly and serine 56 phosphorylation. International    Journal of Cancer 129, 2744-2755.-   85. Huizing, M. T. et al. (1993). Pharmacokinetics of paclitaxel and    metabolites in a randomized comparative study in platinum-pretreated    ovarian cancer patients. Journal of Clinical Oncology 11, 2127-35.-   86. Huizing, M. T., Sparreboom, A., Rosing, H., van Tellingen, O.,    Pinedo, H. M. and Beijnen, J. H. (1995). Quantification of    paclitaxel metabolites in human plasma by high-performance liquid    chromatography. J Chromatogr B Biomed Appl 674, 261-8.-   87. Cao, P., Cai, J. and Gupta, R. C. (2010). Effect of green tea    catechins and hydrolyzable tannins on benzo[a]pyrene-induced DNA    adducts and structure-activity relationship. Chem Res Toxicol 23,    771-7.-   88. Aqil, F., Munagala, R., Vadhanam, M. V., Kausar, H., Jeyabalan,    J., Schultz, D. J. and Gupta, R. C. (2012). Anti-proliferative    activity and protection against oxidative DNA damage by punicalagin    isolated from pomegranate husk. Food Res Int 49, 345-353.-   89. Hemminki, K (2003) DNA adducts, mutations, and cancer.    Carcinogenesis, 14, 2007-12.

It will be understood that various details of the presently disclosedsubject matter can be changed without departing from the scope of thesubject matter disclosed herein. Furthermore, the foregoing descriptionis for the purpose of illustration only, and not for the purpose oflimitation.

What is claimed is:
 1. A composition comprising an effective amount of atherapeutic agent encapsulated by a milk-derived microvesicle, whereinthe therapeutic agent is a nucleic acid.
 2. The composition of claim 1wherein the nucleic acid is a ribonucleic acid (RNA) molecule.
 3. Thecomposition of claim 2 wherein the RNA molecule comprises one or morenon-naturally occurring modifications.
 4. The composition of claim 2wherein the RNA molecule is a non-coding RNA.
 5. The composition ofclaim 2 or claim 3 wherein the RNA molecule is a miRNA molecule.
 6. Thecomposition of claim 5 wherein the miRNA molecule is selected frommiR-155, miR-223 or a combination thereof.
 7. The composition of claim 3wherein the RNA molecule is a siRNA molecule.
 8. The composition ofclaim 2 or claim 3, wherein the RNA molecule is a messenger RNA (mRNA)molecule.
 9. The composition of claim 1 or 2 wherein the milk is rawmilk or colostrum.
 10. The composition of claim 9 wherein the raw milkis bovine raw milk.
 11. The composition of claim 9 wherein the colostrumis bovine colostrum.
 12. The composition of claim 1 or 2 wherein thetherapeutic agent loading is from 3.8% to 65%.
 13. The composition ofclaim 1 or 2, further comprising a pharmaceutically-acceptable vehicle,carrier, or excipient.
 14. A method of modifying an immune response,comprising administering to a subject in need thereof an effectiveamount of a composition of any of claims 1-13.
 15. A method of modifyingan immune response, comprising administering to a subject in needthereof an effective amount of a composition comprising an effectiveamount of a therapeutic agent encapsulated by a milk-derivedmicrovesicle, wherein the therapeutic agent is selected from miR-155,miR-223 or a combination thereof.
 16. Method of treating cancer,comprising administering to a subject in need thereof an effectiveamount composition of of any of claims 1-13.
 17. The method of claim 15,wherein the cancer is selected from the group consisting of lung,breast, cervical, ovarian, prostate, and pancreatic cancer.
 18. A methodof treating an inflammatory disorder, comprising administering aneffective amount of a composition of any of claims 1-13 to a subject inneed of treatment for an inflammatory disorder.
 19. The method of claim17, wherein the inflammatory disorder selected from the group consistingof atherosclerosis; arthritis; inflammation-promoted cancers; asthma;autoimmune uveitis; adoptive immune response; dermatitis; multiplesclerosis; diabetic complications; osteoporosis; Alzheimer's disease;cerebral malaria; hemorrhagic fever; autoimmune disorders; andinflammatory bowel disease.